|
USA, Giugno 2013 -
AUTISMO = 1 bambino
autistico su 26,
non come era nel 2010, 1
su 80 ...
Sindrome
infiammatoria chiamata "Asia" scatenata dai
vaccini
!
ASIA_Sindrome
infiammatoria-dai-vaccini-Riassunto.pdf
Tratto da: http://www.assis.it/wp-content/uploads/2014/12/ASIARiassunto.pdf
... ed e' noto che... le
infiammazioni sono foriere di qualsiasi tipo di
sintomi, che i
medici impreparati
allopati chiamano erroneamente "malattie"....
In CINA dopo le campagne vaccinali esplode
l'Autismo ! - Maggio 2016
http://yournewswire.com/autism-rates-explode-in-asia-after-introducing-western-vaccines/
VERISSIMO, ma non solo l'autismo....ma una
innumerevole sequela di altre
malattie....
Autismo
e non solo dai Vaccini:
Continua da e in:
Autismo Refenze
2
+
Autismo Refenze
- 3 +
Amish senza autismo
perche' NON vaccinano
Ma ricordo che,
molta importanza hanno anche i cibi assunti non
adatti al gruppo sanguigno del soggetto autistico.
vedi QUI:
http://autismovaccini.com/2012/05/01/statistiche-per-lautismo-a-confronto-probabile-1-ogni-29-anziche-1-ogni-88/
Metalli
tossici dei vaccini = Autismo
vedi: PDF - dott.
M. Proietti
http://healthimpactnews.com/2014/the-vaccine-autism-cover-up-how-one-doctors-career-was-destroyed-for-telling-the-truth/
CLAMOROSO:
Nell'estate del
2014 lo scienziato Thompson del
CDC
annunciò che in un famoso articolo pubblicato su
Pediatrics erano stati omessi molti dati relativi
alla popolazione afro della città di Atlanta.
Tale studio “provava la non correlazione” MMR-
autismo
vedi:
http://www.ncbi.nlm.nih.gov/pubmed/14754936
Con le nuove dichiarazioni dello scienziato
Thompson (confessate davanti ad una commissione
statale US), il dr. Hooker ha analizzato di nuovi i
dati che dimostrano senza ombra di dubbio che vi
era un rilevante aumento dei casi di autismo
fra i maschi afroamericani della città di
Atlanta.
Nel febbraio 2004 Thompson scriveva in una sua
e.mail, CHE TROVATE QUI
http://www.naturalnews.com/images/CDC-Gerberding-Warning-Vaccines-Autism.jpg
Nota bene:
Allora era presidente del
CDC USA (Centro
per la prevenzione e il controllo delle
malattie) la dr.ssa Julie Gerberding.
“We’ve not yet met to discuss these matters…I
will be presenting the summary of our results
from the Metropolitan Atlanta Autism
Case-Control Study and I will have to present
several problematic results relating to
statistical associations between the receipt of
MMR vaccine and autism.”
Thompson già metteva in guardia il
CDC
USA circa problematiche relative a forte
correlazione fra
MMR ed
autismo.
Tutto fu insabbiato
L’allora presidente
del CDC USA, ... è ORA dirigente della
Merck
Announces Appointment of Dr. Julie Gerberding
as Executive Vice President for Strategic
Communications, Global Public Policy and
Population Health,
Qui il link:
http://www.mercknewsroom.com/news-release/corporate-news/merck-announces-appointment-dr-julie-gerberding-executive-vice-president
La prova della FRODE del
CDC
per le cause dei
Vaccini
nell'Autismo
- CONFESSIONE di un alto dirigente
CDC, davanti al Congresso US
IMPORTANTE:
PROPOSTA di LEGGE per STUDIO negli USA
sullo STATO di SALUTE FRA BAMBINI VACCINATI e
NON VACCINATI (di nessun vaccino)
Il DISEGNO di LEGGE n° 3069 a FIRMA della
DEPUTATA MALONEY NON E' STATO APPROVATO per
cui E' RIMASTO sulla CARTA.... e NEPPURE
DISCUSSO dal CONGRESSO....a dimostrazione
che NON si vuole fare vere ricerche sui gravi
DANNI dei VACCINI......Big
Pharma ringrazia...
"Noi
medici siamo plagiati, fin dall'inizio, dagli
insegnamenti
universitari
che ci vengono propinati da un manipolo di "professori"
che
hanno il solo interesse di lasciarci
nell'ignoranza sulla vera origine delle malattie.
Alcuni di noi, alla fine, raggiungono la
consapevolezza e mettono in moto delle grosse
energie che provocano reazioni positive nel
Tutto."
By Dott.
Giuseppe De Pace
(medico
ortopedico ospedaliero)
Indagine della
correlazione tra vaccinazione MMR e l’autismo in
Danimarca
http://www.jpands.org/vol9no3/goldman.pdf
http://www.jpands.org/vol9no3/stott.pdf
Una ricerca indipendente
della dottoressa Theresa Deisher sulla correlazione
fra Vaccini ed autismo e non solo...:
http://www.vacciniinforma.it/?p=2314
Sintesi:
Ricordiamo la pubblicazione nell’anno 2014 dello
studio del Dr Theresa Deisher. Questo continua a far
parlare di sé . Cerchiamo di ricordare anche qualche
fonte in merito.
Uno studio pubblicato
http://www.academicjournals.org/journal/JPHE/article-abstract/C98151247042
rivela
una significativa correlazione tra il disturbo
autistico (AD) e i vaccini
MPR
(morbillo, parotite e rosolia), quello per la
varicella e quello per l’epatite-A.
Utilizzando l’analisi statistica e i dati forniti
dai governi di Stati Uniti, Regno Unito, Danimarca e
Australia occidentale, gli scienziati del Sound
Choice Pharmaceutical Institute (SCPI) hanno
trovato che l’aumento nella diffusione
dell’autismo corrisponde all’introduzione di
vaccini che utilizzano
cellule umane fetali abortive
e contaminanti retrovirali.
Ancora più allarmante quanto afferma la Dr Theresa
Deisher, autrice dello studio, laureata
in Fisiologia Cellulare e Molecolare presso
la Stanford University e fondatrice dello SCPI:
“I vaccini contaminati da cellule umane fetali non
solo sono associati con disturbo
autistico
in tutto il mondo, ma anche con un’epidemia di
leucemia infantile e linfomi.”
Un nuovo studio quindi – che arriva
contemporaneamente alle notizia che il
CDC
ha deliberatamente nascosto la prova del
significativo aumento di autismo tra i bambini
afro-americani che erano stati vaccinati prima di 36
mesi di età. – solleva seri interrogativi sulla
sicurezza dei vaccini, in particolare per la
presenza in essi di cellule umane fetali abortive.
Ancora un nuovo studio di cui in Italia non avremo
notizia dalla stampa ufficiale, un nuovo studio
che sembra non interessare nessuno.
Da parte nostra crediamo che le scoperte dello
studio dovrebbero produrre quantomeno un’inchiesta
immediata da parte della
FDA,
se non un aperto divieto dell’uso di cellule umane
fetali abortive come substrato per la produzione di
vaccini.
La Dr. Theresa Deisher, un dottorato di ricerca in
Fisiologia Cellulare e Molecolare presso la Stanford
University: “E ‘possibile che questi frammenti
contaminanti potrebbero essere incorporati nel
genoma di un bambino e perturbare la funzione del
gene normale, portando a fenotipi autistici.”
Si può leggere lo studio completo
QUI
La Dr. Theresa Deisher ha trascorso oltre 19 anni
nel settore della biotecnologia con varie aziende
come la Genentech, Repligen, Amgen e le sue scoperte
hanno portato a sperimentazioni cliniche per
patologie multiple.
I Tribunali anche USA, confermano
tranquillamente che il vaccino
MMR causa l'autismo. Austin (USA) - 27
Luglio 2013
Dopo decenni di appassionato dibattito, per i
genitori che probabilmente hanno perso i ripetuti
ricorsi richiesti dalle aziende farmaceutiche e
governi, che i vaccini infatti causano l'autismo.
Per i genitori interessati alla ricerca della
verità, vale la pena ricordare che le stesse persone
che possiedono le aziende farmaceutiche di tutto il
mondo possono anche possedere agenzie di stampa
americane.
La Ricerca di informazioni prive di propaganda è
stata fino ad ora molto difficile.
Ma Whiteout Press non è qui per sostenere o
contrastare i vaccini. Siamo qui per portare i
lettori la notizia che è il tema e’ in black-out,
cover-up e censurato dalle autorita’Sanitarie e
Governative.
Tratto da:
http://www.whiteoutpress.com/timeless/courts-quietly-confirm-mmr-vaccine-causes-autism/
PREMESSA doverosa ed
IMPORTANTE:
Qui troverete una raccolta di studi che confermano che
il Mercurio
DANNEGGIA
la salute di coloro che lo introducono nel
proprio corpo - Pero' occorre ricordare, per coloro che
non lo sanno, che il mercurio e' stato presente nelle
amalgami dentali
(per 50 anni circa) e sotto forma di
Tiomersale o Thiomersal,
e' stato introdotto
volutamente per ben 50 anni nei
vaccini
di TUTTO il mondo
generando
gli stessi problemi
ben descritti in questi
studi - Il mercurio e' anche
presente in certi cibi, specie nei grossi pesci.
Il mercurio e' stato eliminato dai vaccini, prima
negli USA e successivamente negli altri stati del mondo,
per lasciare che le
case farmaceutiche
esaurissero le loro
scorte
di vaccini
al mercurio....e
cio' con il consenso degli stati (ministeri della
sanita')....e SOLO DOPO che da tutto il mondo nei
vari stati si sono
levate le
proteste di cittadini,
medici, ricercatori, associazioni di malati.....
INOLTRE i Danni dei
Vaccini non si limitano agli
ingredienti pericolosi che essi
contengono, ma anche ai
virus, batteri, spore utilizzati per i
vaccini,
anche se, come raccontano, "inattivati", hanno caratteristiche di
grave
pericolosita' perche' sono sostanze
ESTRANEE
(i virus ed
eccipienti) e
microorganismi (solo i batteri)
all'organismo e quindi generano reazioni anomale
le piu' disparate ed inaspettate; e' il principio
stesso dell'atto vaccinale ad essere discusso e
RIGETTATO
in toto
!
Gli esperti di
vaccini
del
CDC, hanno spesso
conflitti di
interesse
- 18/03/2010
CDC e
Conflitti di interesse - 1
+
CDC e Conflitti
di interesse - 2
+
CDC e Conflitti
di interesse - 3
+
Corruzione
+
Danni dei
Vaccini +
Contro Immunizzazione
CDC
conflitti di
interesse
anche per i vaccini +
anche per la FDA
http://healthimpactnews.com/2014/cdcs-purchase-of-4-billion-of-vaccines-a-conflict-of-interest-in-overseeing-vaccine-safety/
Davvero inquietante !
Questo medico il Dott.
Andrew Moulden è MORTO (probabilmente
assassinato) in modo inspiegabile nel
novembre 2013 al età di 49, subito dopo
aver pubblicato Le SUE RICERCHE che
DIMOSTRANO il DANNO CAUSATO dai VACCINI,
RICONOSCIBILI SOLO da un SEMPLICE ESAME
ESTERNO
http://vaccineimpact.com/2015/dr-andrew-moulden-learning-to-identify-vaccine-damage/
Parlamentari pagati dalle Lobbies ? -
Roma Ott. 2013
L'intervista a un assistente di un Senatore
che svelerebbe i traffici illeciti tra
parlamentari e
Lobbies.
Video dell'intervista:
http://www.video.mediaset.it/video/iene/puntata/390060/roma-parlamentari-pagati-dalle-lobbies.html
Informatore dei
CDC
CONFESSA la FRODE e le FALSIFICAZIONI sugli
studi della correlazione VACCINO=AUTISMO
Sentenza 2012 - Trib. Rimini su Vaccini=Autismo
vedi:
Amish senza autismo perche'
NON vaccinano +
1000
studi sui Danni dei Vaccini
+
Bibliografia 3
+
Bibliografia 4 +
Sostanze
eterologhe nei vaccini e reazioni
+
Autismo
+ Big
Pharma
+
INGREDIENTI TOSSICI anche OCCULTI,
di alcuni VACCINI analizzati +
Contenuto nel vaccini Trivalenti
(difpertal) +
Come si producono i Vaccini
+
Falsita'
della medicina ufficiale
Negli USA dal 1988
le vaccinazioni si sono triplicate ed i casi di
Autismo
sono aumentati del 270 % !!
Il
libro
ormai esaurito, del
dott.
Massimo Montinari
NO
Vaccini, no Autismo:
http://homefirst.com/no_vaccines_no_autism
Killing Us Softly (non e’ in italiano):
http://www.youtube.com/watch?v=Pjt77lBNjwM&feature=related
1. Hepatitis
B Vaccination of Male Neonates and Autism
Annals of Epidemiology, September 2009
CM Gallagher, MS Goodman, Stony Brook University Medical
Center
Boys vaccinated as neonates had threefold greater odds
for autism diagnosis compared to boys never vaccinated
or vaccinated after the first month of life.
2. Porphyrinuria
in childhood autistic disorder: Implications for
environmental toxicity
Toxicology and Applied Pharmacology, 2006
Robert Natafa, et al, Laboratoire Philippe Auguste,
Paris, France
These data implicate environmental toxicity in childhood
autistic disorder.
3. Theoretical
aspects of autism: Causes—A review
Journal of Immunotoxicology, January-March 2011
Helen V. Ratajczak, PhD
Autism could result from more than one cause, with
different manifestations in different individuals that
share common symptoms. Documented causes of autism
include genetic mutations and/or deletions, viral
infections, and encephalitis following vaccination.
4. Uncoupling
of ATP-mediated Calcium Signaling and Dysregulated IL-6
Secretion in Dendritic Cells by Nanomolar Thimerosal
Environmental Health Perspectives, July 2006.
Samuel R. Goth, Ruth A. Chu Jeffrey P. Gregg
This study demonstrates that very low-levels of
Thimerosal can contribute to immune system disregulation.
5. Gender-selective
toxicity of thimerosal
Exp Toxicol Pathol. 2009 Mar;61(2):133-6. Epub 2008 Sep
3.
Branch DR, Departments of Medicine and Laboratory
Medicine and Pathobiology, University of Toronto
A recent report shows a correlation of the historical
use of thimerosal in therapeutic immunizations with the
subsequent development of autism; however, this
association remains controversial. Autism occurs
approximately four times more frequently in males
compared to females; thus, studies of thimerosal
toxicity should take into consideration gender-selective
effects. The present study was originally undertaken to
determine the maximum tolerated dose (MTD) of
thimersosal in male and female CD1 mice. However, during
the limited MTD studies, it became apparent that
thimerosal has a differential MTD that depends on
whether the mouse is male or female.
6. Comparison
of Blood and Brain Mercury Levels in Infant monkeys
exposed to Vaccines Containing Thimerosal
Environmental Health Perspectives, Aug 2005.
Thomas Burbacher, PhD, University of Washington
This study demonstrates clearly and unequivocally that
ethyl mercury, the kind of mercury found in vaccines,
not only ends up in the brain, but leaves double the
amount of inorganic mercury as methyl mercury, the kind
of mercury found in fish. This work is groundbreaking
because little is known about ethyl mercury, and many
health authorities have asserted that the mercury found
in vaccines is the “safe kind.” This study also delivers
a strong rebuke of the Institute of Medicine’s
recommendation in 2004 to no longer pursue the
mercury-autism connection.
7. Increases
in the number of reactive glia in the visual cortex of
Macaca fascicularis following subclinical long-term
methyl mercury exposure
Toxicology and Applied Pharmacology, 1994
Charleston JS et al, Department of Pathology, School of
Medicine, University of Washington
The identities of the reactive glial cells and the
implications for the long-term function and
survivability of the neurons due to changes in the glial
population following subclinical long-term exposure to
mercury are discussed.
8. Neuroglial
Activation and Neuroinflammation in the Brain of
Patients with Autism
Annals of Neurology, Feb 2005.
Diana L. Vargas, MD [Johns Hopkins University]
This study, performed independently and using a
different methodology than Dr. Herbert (see above)
reached the same conclusion: the brains of autistic
children are suffering from inflammation.
9. Autism:
A Brain Disorder, or a Disorder That Affects the Brain?
Clinical Neuropsychiatry, 2005
Martha R. Herbert M.D., Ph.D., Harvard University
Autism is defined behaviorally, as a syndrome of
abnormalities involving language, social reciprocity and
hyperfocus or reduced behavioral flexibility. It is
clearly heterogeneous, and it can be accompanied by
unusual talents as well as by impairments, but its
underlying biological and genetic basis in unknown.
Autism has been modeled as a brain-based, strongly
genetic disorder, but emerging findings and hypotheses
support a broader model of the condition as a
genetically influenced and systemic.
10. Activation
of Methionine Synthase by Insulin-like Growth Factor-1
and Dopamine: a Target for Neurodevelopmental Toxins and
Thimerosal
Molecular Psychiatry, July 2004.
Richard C. Deth, PhD [Northeastern University]
This study demonstrates how Thimerosal inhibits
methylation, a central driver of cellular communication
and development.
11. Validation
of the Phenomenon of Autistic Regression Using Home
Videotapes
Archives of General Psychiatry, 2005
Emily Werner, PhD; Geraldine Dawson, PhD, University of
Washington
Conclusion This study validates the existence of early
autistic regression.
12. Blood
Levels of Mercury Are Related to Diagnosis of Autism: A
Reanalysis of an Important Data Set
Journal of Child Neurology, 2007
M. Catherine DeSoto, PhD, Robert T. Hitlan, PhD
-Department of Psychology, University of Northern Iowa
Excerpt: “We have reanalyzed the data set originally
reported by Ip et al. in 2004 and have found that the
original p value was in error and that a significant
relation does exist between the blood levels of mercury
and diagnosis of an autism spectrum disorder. Moreover,
the hair sample analysis results offer some support for
the idea that persons with autism may be less efficient
and more variable at eliminating mercury from the
blood.”
13. Developmental
Regression and Mitochondrial Dysfunction in a Child With
Autism
Journal of Child Neurology, February 2006
Jon S. Poling, MD, PhD, Department of Neurology and
Neurosurgery, Johns Hopkins Hospital
Excerpt: “Children who have (mitochondrial-related)
dysfunctional cellular energy metabolism might be more
prone to undergo autistic regression between 18 and 30
months of age if they also have infections or
immunizations at the same time.”
14. Oxidative
Stress in Autism: Elevated Cerebellar 3-nitrotyrosine
Levels
American Journal of Biochemistry and Biotechnology,
2008
Elizabeth M. Sajdel-Sulkowska, – Dept of Psychiatry,
Harvard Medical School
Excerpt: The preliminary data suggest a need for more
extensive studies of oxidative stress, its relationship
to the environmental factors and its possible
attenuation by antioxidants in autism.”
15. Large
Brains in Autism: The Challenge of Pervasive Abnormality
The Neuroscientist, 2005.
Martha Herbert, MD, PhD, Harvard University
This study helps refute the notion that the brains of
autistic children are simply wired differently and
notes, “neuroinflammation appears to be present in
autistic brain tissue from childhood through adulthood.”
Dr. Herbert suggests that chronic disease or an external
environmental source (like heavy metals) may be causing
the inflammation.
16. Evidence
of Toxicity, Oxidative Stress, and Neuronal Insult in
Autism
Journal of Toxicology and Environmental Health, Nov-Dec
2006.
Janet Kern, Anne Jones, Department of Psychiatry,
University of Texas Southwestern Medical Center
“This article discusses the evidence for the case that
some children with autism may become autistic from
neuronal cell death or brain damage sometime after birth
as result of insult; and addresses the hypotheses that
toxicity and oxidative stress may be a cause of neuronal
insult in autism… the article discusses what may be
happening over the course of development and the
multiple factors that may interplay and make these
children more vulnerable to toxicity, oxidative stress,
and neuronal insult.”
17. Oxidative
Stress in Autism
Pathophysiology, 2006.
Abha Chauhan, Ved Chauhan
This study provides a helpful overview of the growing
evidence supporting the link between oxidative stress
and autism.
18. Thimerosal
Neurotoxicity is Associated with Glutathione Depletion:
Protection with Glutathione Precursors
Neurotoxicology, Jan 2005.
S. Jill James, PhD, University of Arkansas
This recent study demonstrates that Thimerosal lowers or
inhibits the body’s ability to produce Glutathione, an
antioxidant and the body’s primary cellular-level
defense against mercury.
19. Aluminum
adjuvant linked to gulf war illness induces motor neuron
death in mice
Neuromolecular Medicine, 2007
Christopher Shaw, Ph.D., Department of Ophthalmology and
Program in Neuroscience, University of British Columbia
This study demonstrates the extreme toxicity of the
aluminum adjuvant used as a preservative in vaccines.
20. Environmental
mercury release, special education rates, and autism
disorder: an ecological study of Texas
Health & Place, 2006
Raymond F. Palmer, University of Texas Health Science
Center
This study demonstrated the correlation between
environmental mercury and autism rates in Texas.
21. Autism
Spectrum Disorders in Relation to Distribution of
Hazardous Air Pollutants in the SF Bay Area
Environmental Health Perspectives, September, 2006
Gayle Windham, Div. of Environmental and Occupational
Disease Control, California Department of Health
Services
Excerpt: “Our results suggest a potential association
between autism and estimated metal concentrations, and
possibly solvents, in ambient air around the birth
residence.”
22. A
Case Series of Children with Apparent Mercury Toxic
Encephalopathies Manifesting with Clinical Symptoms of
Regressive Autistic Disorder
Journal of Toxicology and Environmental Health, 2007
David A. Geier, Mark R. Geier
This study reviewed the case histories and medical
profiles of nine autistic children and concluded that
eight of the nine children were mercury toxic and this
toxicity manifested itself in a manner consistent with
Autism Spectrum Disorders.
23. Attention-deficit
hyperactivity disorder and blood mercury level: a
case-control study in chinese children
Neuropediatrics, August 2006 – P.R. Kong
Excerpt: “There was significant difference in blood
mercury levels between cases and controls, which
persists after adjustment for age, gender and parental
occupational status. The geometric mean blood mercury
level was also significantly higher in children with
inattentive and combined subtypes of ADHD. High blood
mercury level was associated with ADHD. Whether the
relationship is causal requires further studies.”
24. The
Changing Prevalence of Autism In California
Journal of Autism and Developmental Disorders, April
2003
Mark F. Blaxill, David S. Baskin, and Walter O. Spitzer
This study helps to refute the supposition made by some
researchers that autism’s epidemic may only be due to
“diagnostic substitution”.
25. Mitochondrial
Energy-Deficient Endophenotype in Autism
American Journal of Biochemistry and Biotechnology 2008
J. Jay Gargus and Faiqa Imtiaz, School of Medicine,
University of California, Irvine,
While evidence points to a multigenic etiology of most
autism, the pathophysiology of the disorder has yet to
be defined and the underlying genes and biochemical
pathways they subserve remain unknown.
26. Bridging
from Cells to Cognition in Autism Pathophysiology:
Biological Pathways to Defective Brain Function and
Plasticity
American Journal of Biochemistry and Biotechnology 2008
Matthew P. Anderson, Brian S. Hooker and Martha R.
Herbert, Cambridge Health Alliance/Harvard Medical
School/Beth Israel Deaconess Medical Center
We review evidence to support a model where the disease
process underlying autism may begin when an in utero or
early postnatal environmental, infectious, seizure, or
autoimmune insult triggers an immune response that
increases reactive oxygen species (ROS) production in
the brain that leads to DNA damage (nuclear and
mitochondrial) and metabolic enzyme blockade and that
these inflammatory and oxidative stressors persist
beyond early development (with potential further
exacerbations), producing ongoing functional
consequences.
27. Heavy-Metal
Toxicity—With Emphasis on Mercury
John Neustadt, ND, and Steve
Pieczenik, MD, PhD
Conclusion: Metals are ubiquitous in our environment,
and exposure to them is inevitable. However, not all
people accumulate toxic levels of metals or exhibit
symptoms of metal toxicity, suggesting that genetics
play a role in their potential to damage health.
28. Evidence
of Mitochondrial Dysfunction in Autism and Implications
for Treatment
American Journal of Biochemistry and Biotechnology
Daniel A. Rossignol, J. Jeffrey Bradstreet
MtD and oxidative stress may also explain the high male
to female ratio found in autism due to increased male
vulnerability to these dysfunctions.
29. Proximity
to point sources of environmental mercury release as a
predictor of autism prevalence
Health & Place, 2008
Raymond F. Palmer et al, University of Texas Health
Science Center
This study should be viewed as hypothesis-generating – a
first step in examining the potential role of
environmental mercury and childhood developmental
disorders. Nothing is known about specific exposure
routes, dosage, timing, and individual susceptibility.
We suspect that persistent low-dose exposures to various
environmental toxicants, including mercury, that occur
during critical windows of neural development among
genetically susceptible children (with a diminished
capacity for metabolizing accumulated toxicants) may
increase the risk for developmental disorders such as
autism.
30. Epidemiology
of autism spectrum disorder in Portugal: prevalence,
clinical characterization, and medical conditions
Developmental Medicine & Child Neurology, 2007
Guiomar Oliveira MD PhD et al, Centro de Desenvolvimento
da Criança, Hospital Pediátrico de Coimbra; Assunção
Ataíde BSc, Direcção Regional de Educação do Centro
Coimbra;
The objective of this study was to estimate the
prevalence of autistic spectrum disorder (ASD) and
identify its clinical characterization, and medical
conditions in a paediatric population in Portugal
Fonte:
http://circleofdocs.com/30-solid-scientific-studies-that-prove-vaccines-cause-autism/
LA VALANGA DEI NUOVI
STUDI DI CORRELAZIONE AUTISMO-MERCURIO +
Autismo Referenze 2 +
Autismo - 3
J Immunotoxicol. 2011 Jan-Mar;8(1):68-79.
Theoretical aspects of autism: causes--a review.
Ratajczak HV - Source: hratajcz@comcast.net
Abstract
Autism, a member of the pervasive developmental
disorders (PDDs), has been increasing dramatically since
its description by Leo Kanner in 1943. First estimated
to occur in 4 to 5 per 10,000 children, the incidence of
autism is now 1 per 110 in the United States, and 1 per
64 in the United Kingdom, with similar incidences
throughout the world. Searching information from 1943 to
the present in PubMed and Ovid Medline databases, this
review summarizes results that correlate the timing of
changes in incidence with environmental changes. Autism
could result from more than one cause, with different
manifestations in different individuals that share
common symptoms. Documented causes of autism include
genetic mutations and/or deletions, viral infections,
and encephalitis following vaccination. Therefore,
autism is the result of genetic defects and/or
inflammation of the brain. The inflammation could be
caused by a defective placenta, immature blood-brain
barrier, the immune response of the mother to infection
while pregnant, a premature birth, encephalitis in the
child after birth, or a toxic environment.
Comment
Response to "Theoretical aspects of autism: causes--a
review" by Ratajczak, HV (Journal of Immunotoxicology
8:68-79, 2011). [J Immunotoxicol. 2011]
Response to "Theoretical aspects of autism: causes--a
review" by Ratajczak, HV (Journal of Immunotoxicology
8:68-79, 2011).Dewitt JC, Dietert RR. J Immunotoxicol.
2011 Jul-Sep; 8(3):195-7. Epub 2011 May 31.
Coincidental associations do not provide proof for the
etiology of autism. [J Immunotoxicol. 2011]
Coincidental associations do not provide proof for the
etiology of autism.Kennedy JS, Lawrence DA. J
Immunotoxicol. 2011 Jul-Sep; 8(3):198-203. Epub 2011 Jun
16.
PMID: 21299355 [PubMed - indexed for
MEDLINE]
Traduzione:
J Immunotoxicol. 2011 Gen-Mar, 8 (1) :68-79.
Aspetti teorici dell'autismo: cause - una recensione. By
Ratajczak HV - Fonte: hratajcz@comcast.net
Estratto
Autismo, un membro dei disturbi pervasivi dello sviluppo
(PDD), è aumentata drammaticamente dalla sua descrizione
da parte di Leo Kanner nel 1943. Prima era stimato in 4
o 5 ogni 10.000 bambini, l'incidenza oggi (2010)
dell'autismo è 1 per 110 negli
Stati Uniti, e 1
per 64 nel Regno Unito, con incidenze simili in
tutto il mondo.
Ricerca di informazioni dal 1943 ad oggi su PubMed e
Ovid banche dati Medline, questa recensione riassume i
risultati che correlano i tempi di cambiamento
nell'incidenza con i cambiamenti ambientali.
L’Autismo potrebbe derivare da più di una causa, con
manifestazioni differenti in differenti individui che
condividono sintomi comuni.
Cause documentate di autismo comprendono
mutazioni genetiche
e / o delezioni, infezioni virali, e in seguito ad
encefalite da
vaccinazione.
Pertanto, l'autismo è il risultato di
difetti genetici
e/o
infiammazione del
cervello.
L'infiammazione può essere causata anche da un difetto
placenta, immaturita' della barriera emato-encefalica,
la risposta immunitaria della madre ad infezione durante
la gravidanza, un parto prematuro, encefalite nel
bambino dopo la nascita, od in un ambiente tossico.
Commenti
Risposta a "Aspetti teorici dell'autismo: cause - una
recensione" di Ratajczak, HV (Journal of
Immunotossicologia 8:68-79, 2011). [J Immunotoxicol.
2011]
Risposta a "Aspetti teorici dell'autismo: cause - una
recensione" di Ratajczak, HV (Journal of
Immunotossicologia 8:68-79, 2011) Dewitt JC, RR. Dietert.
J Immunotoxicol. 2011 Lug-Set, 8 (3) :195-7. Epub 2011
Maggio 31.
Associazioni coincidenti non forniscono prova per
l'eziologia dell'autismo. [J Immunotoxicol. 2011]
Associazioni coincidenti non forniscono prova per
l'eziologia dell'autismo. Kennedy JS, Lawrence DA.
J Immunotoxicol. 2011 Lug-Set, 8 (3)
:198-203. Epub 2011 Jun 16.
PMID: 21299355 [PubMed - indexed for MEDLINE]
Studio rivela
un'associazione positiva tra autismo e vaccini -
Giu. 2011
Un recente studio (pubblicazione online: 26 mag. 2011)
pubblicato sul Journal of Rapport sulla salute e
Tossicologia Ambientale, di cui il titolo del report,
che un'associazione positiva
è stata trovata tra
autismo e vaccini:
un'associazione positiva trovata tra Prevalenza autismo
Vaccinazioni dell'infanzia e l'assorbimento attraverso
la popolazione degli Stati Uniti .
L'abstract studio attribuisce la conclusione, nel
contesto del pensiero attuale che vede l'autismo come
l'interazione tra predisposizione genetica e fattori
ambientali. Essa individua anche i difetti in alcuni
degli studi più importanti che sono propagandati come "debunking"
ogni possibile collegamento vaccino autismo.
To cite this Article DeLong, Gayle(2011) 'A Positive
Association found between Autism Prevalence and
Childhood Vaccination uptake across the U.S. Population',
Journal of Toxicology and Environmental Health, Part A,
74: 14, 903 —916
To link to this Article: DOI:
10.1080/15287394.2011.573736
URL:
http://dx.doi.org/10.1080/15287394.2011.573736 -
vedi:
QUI il PDF
The body detoxifies itself
(James et al. 2004).
This difficulty in detoxifying could be associated with
metals from vaccines being sequestered in the brain and
causing neurological damage (Kern et al. 2007).
Vaccines may also increase the oxidative stress of
children with preexisting mitochondrial dysfunctions to
such an extent that the children develop autism (Poling
et al. 2006).
In general, susceptibility to developing a neurological
disability after exposure to an environmental insult
such as a vaccine depends on factors such as a child¡¯s
age at time of exposure, amount of exposure, genetic
predisposition, and stress (Kern and Jones 2006).
Compounding these biological issues is the fact that the
number of vaccinations recommended for U.S. children by
age 2 years has more than tripled, from 8 vaccinations
in 1983 to 27 in 2010 (Centers for Disease Control and
Prevention 1983; 2010). Although individual vaccines are
tested for safety and efficacy, no study has ever
examined the safety of the entire vaccination schedule
recommended for U.S. children by the CDC. Neither the
short-term nor chronic interactions among all the
vaccines in a childs recommended schedule have ever
been tested.
Examining the relationship between the proportion of
children who receive vaccinations and the prevalence of
autism may provide insights into whether autism is an
adverse reaction to vaccinations. If an association
between receiving vaccinations and developing autism is
found to exist across geography and through time,
further investigation into the hypothesis is warranted.
Il
danno da vaccini è una causa
documentata di autismo
E' stata pubblicata in questi giorni sulla importante
rivista scientifica Journal of Immunotoxicology, 2011;
8(1): 68–79, una nuova revisione di studi che esamina le
varie cause ambientali dell'autismo, tra cui i vaccini e
i loro componenti.
Leggere il pdf:
Helen Ratajczak, l'autrice, è
una ricercatrice della Boehringer Ingelheim
Pharmaceuticals che ha pubblicato, come autrice o
coautrice,
41 articoli su PubMed. E' anche stata coautrice nel
2006 di uno studio per l'FDA
e, nello stesso anno, è stata eletta Presidente della
sezione Nord Est dell'Istituto di Tossicologia. E' una
scienziata seria e rispettata che, in questa recensione.
Discute la presenza di
DNA di feti umani nell'
MMR II e nei vaccini Varivax. Questi alcuni stralci
dal suo lavoro sull'autismo su Immunotoxicology:
ABSTRACT
L'autismo può risultare da più
di una causa, con differenti manifestazioni in
differenti soggetti che mostrano sintomi comuni.
Le cause documentate di autismo comprendono mutazioni
genetiche e/o delezioni, infezioni virali e encefaliti
in seguito a vaccinazioni.
L'AUMENTO della DIFFUSIONE
dell'ASD E' una REALTA'
In generale,
l'incremento della
diffusione dell'autismo non deve considerarsi il
risultato della avvenuta riclassificazione.
Sebbene le diagnosi di autismo siano aumentate, non c'è
infatti alcuna diminuzione corrispondente in altre
categorie diagnostiche, i dati del Ministero
dell'Istruzione, e in particolare quelli provenienti dal
Dipartimento per l'Istruzione Speciale, mostrano un
significativo aumento della diffusione dell'autismo tra
i bambini, e specialmente tra quelli nati tra il 1987 e
il 1992. In quegli anni, la diffusione dell'autismo su
10.000 nati salì di circa il 50% ogni 2 anni: 5.3 nel
1984, 7.8 nel 1986, 11.8 nel 1988, e 18.3 nel1990.
In
quel periodo non ci furono cambiamenti nella diffusione
di ritardo mentale, ritardo del linguaggio o di lesione
cerebrale, la qual cosa indica che l'aumento
dell'autismo c'è effettivamente stato.
La nuova versione del vaccino contro morbillo, rosolia e
parotite (MMR II) che non contiene
Thimerosal venne
introdotta nel 1979.
Dal 1983, venne utilizzata solo
questa nuova versione.
L'autismo negli Stati Uniti
ebbe un drammatico picco tra il 1983 e il1990
passando da 4–5 casi ogni 10.000 nati a 1 su 500.
Nel 1988, venivano consigliate due dosi dell'MMR II per
immunizzare quei soggetti che non rispondevano al primo
vaccino. Un picco nella diffusione dell'autismo venne
quindi ad associarsi all'aggiunta della seconda dose di
MMR II.
Nel 1988, l'MMR II
venne usato anche in Inghilterra nella quale oggi il
tasso di diffusione è arrivato a 1 ogni 64.
Anche in Canada, Danimarca e Giappone si sono avuti
importanti incrementi della diffusione dell'autismo. E'
importante notare che diversamente dal primo MMR, la
componente per la rosolia dell' MMR II è stata propagata
in membrana cellulare umana derivata da tessuti dei
polmoni embrionali (Merck
and Co., Inc., 2010).
Il vaccino MMR II è
contaminato con DNA
umano proveniente dalla
membrana cellulare. Questo DNA umano potrebbe essere
la causa del picco nella diffusione dell'autismo.
Un successivo picco si ebbe poi nel 1995 quando il
vaccino per la varicella venne fatto crescere in tessuti
fetali umani (Merck
and Co., Inc., 2001; Breuer, 2003).
L'attuale incidenza negli Stati Uniti è
approssimativamente di 1 su 80 (anno 2008).
Il DNA umano dai vaccini può
essere inserito casualmente nei geni di chi ha fatto il
vaccino da ricombinazioni omologhe, un processo che
avviene spontaneamente solo all'interno di una specie.
Punti caldi per l'inserimento di questo DNA sono stati
trovati nel cromosoma X in otto geni associati
all'autismo coinvolti nella formazione di sinapsi nei
nervi, nello sviluppo del sistema nervoso centrale e
nella funzione mitocondriale (Deisher, 2010).
Tutto
questo potrebbe fornire delle spiegazioni del perchè
l'autismo è in predominanza una malattia che colpisce
maggiormente i maschi. Messi assieme, questi dati
sostengono l'ipotesi che residui di DNA umano in alcuni
vaccini possano provocare autismo.
VACCINI
I dati sull'incidenza
e prevalenza indicano che il momento di introduzione dei
vaccini e le modificazioni nel tipo e nell'incremento
del numero dei vaccini inoculati contemporaneamente
implica che i vaccini sono causa di autismo.
La tabella attuale raccomandata per l'immunizzazione
per bambini dai 0 ai 6 anni negli Stati Uniti
include sei vaccini ai due mesi di età e 9 a 12-15 mesi,
un incremento che va oltre le raccomandazioni di sei
anni prima.
Il
sistema immunitario
è particolarmente sensibile a due mesi di età. In questo
modo, il sistema
immunitario di un neonato viene
compromesso a due mesi.
Una minaccia attraverso
così tanti vaccini nel momento in cui il
sistema immunitario è
compromesso può contribuire all'insorgenza
dell'autismo.
ANTIGENI VACCINALI
Molti genitori affermano che
lo sviluppo dei loro figli era normale
finchè non hanno fatto i
vaccini all'età di circa 18 mesi.
L'organismo vaccino potrebbe esserne la causa. Una
ipotesi, relativa al vaccino della
pertosse è che la tossina
pertosse contenuta in questo vaccino causi una
separazione della proteina G-alpha dai recettori
retinoidi in bambini geneticamente a rischio.
RIEPILOGO e CONCLUSIONI
L'autismo ha raggiunto
proporzioni epidemiche. Con una diffusione di 1 su110
negli Stati Uniti, 1 su 64 in Inghilterra e United
Kingdom, e numeri simili in molti altri paesi, è
evidente una situazione di pericolo per le future
generazioni. Integrando i dati qui presentati, una
ipotesi è che l'autismo sia il risultato di difetti
genetici, con l'effetto contributivo dell'età avanzata
dei genitori, e/o
infiammazione del
cervello.
L'infiammazione potrebbe essere causata da un gran
numero di agenti tossici ambientali, infezioni e
co-morbidità in soggetti geneticamente predisposti ai
disordini dello
sviluppo.
Tratto da: emergenzaautismo.org
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
N Engl J Med. 2002 Nov 7;347(19):1477-82.
A population-based study of measles,
mumps, and rubella vaccination and autism.
Madsen KM,
Hviid A,
Vestergaard M,
Schendel D,
Wohlfahrt J,
Thorsen P,
Olsen J,
Melbye M.
Source: Danish Epidemiology Science Center, Department
of Epidemiology and Social Medicine, Arhus, Denmark.
kmm@dadlnet.dk
Abstract
BACKGROUND:
It has been suggested that vaccination against measles,
mumps, and rubella (MMR) is a cause of autism.
METHODS:
We conducted a retrospective cohort study of all
children born in Denmark from January 1991 through
December 1998.
The cohort was selected on the basis of
data from the Danish Civil Registration System, which
assigns a unique identification number to every
live-born infant and new resident in Denmark.
MMR-vaccination status was obtained from the Danish
National Board of Health. Information on the children's
autism status was obtained from the Danish Psychiatric
Central Register, which contains information on all
diagnoses received by patients in psychiatric hospitals
and outpatient clinics in Denmark. We obtained
information on potential confounders from the Danish
Medical Birth Registry, the National Hospital Registry,
and Statistics Denmark.
RESULTS:
Of the 537,303 children in the cohort (representing
2,129,864 person-years), 440,655 (82.0 percent) had
received the MMR vaccine. We identified 316 children
with a diagnosis of autistic disorder and 422 with a
diagnosis of other autistic-spectrum disorders.
After
adjustment for potential confounders, the relative risk
of autistic disorder in the group of vaccinated children,
as compared with the unvaccinated group, was 0.92 (95
percent confidence interval, 0.68 to 1.24), and the
relative risk of another autistic-spectrum disorder was
0.83 (95 percent confidence interval, 0.65 to 1.07).
There was no association between the age at the time of
vaccination, the time since vaccination, or the date of
vaccination and the development of autistic disorder.
CONCLUSIONS:
This study provides strong evidence against the
hypothesis that MMR vaccination causes autism.
Copyright 2002 Massachusetts Medical Society
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Collegamento Scientifico
tra Autismo e Vaccini - per il
meccanismo dei danni dei vaccini
Il
Center for Modeling Optimal Outcomes ha fatto una
sorprendente scoperta mentre stava svolgendo una ricerca
sull’applicazione della neuroscienza nel business.
Il Centro ha scoperto delle relazioni uniche tra le
varie sostanze chimiche del cervello (neuroormoni,
neutrotrasmettitori, ecc.) e ha provato ad applicare
questo modello alla letteratura scientifica.
Con stupore questo gruppo di studiosi ha così scoperto
che questo modello di relazioni poteva essere applicato
ai processi scientifici per mantenere l’equilibrio
(relazioni omeostatiche) in tutti i campi della scienza,
dalle particelle subatomiche, alla chimica, alle
sostanze biologiche.
L’intera comunità scientifica sa che l’omeostasi esiste,
ma questa conoscenza non era ancora stata convertita in
un modello replicabile, passo dopo passo. Il Centro ora
ha identificato con precisione tale processo esplicito.
Studiando in particolare l’autismo, il gruppo del Center's Life Sciences è stato in grado di formulare un
modello scientificamente verificabile per un altamente
probabile percorso causale dell’autismo.
Applicando il loro modello, è diventato apparente che
l’autismo è un risultato di diverse variabili e che
quando la relazione omeostatica di ciascuna di queste
variabili viene distrutta, si forma lo scenario di una
“tempesta perfetta” che dà come risultato l’autismo.
L’applicazione del modello ha identificato diverse
variabili che spiegano la proporzione superiore maschile
di malati di autismo (4 maschi a 1 femmina) e spiegano
perché non tutti i bambini maschi si ammalano di
autismo.
Ora la
comunità scientifica dovrà validare queste scoperte ma,
secondo il Centro, il modello di verifica delle
relazioni omeostatiche indica che il fattore scatenante
dell’autismo sia uno sbilanciamento tra una coppia di
aminoacidi neurotrasmettitori, il glutamato e la glicina.
William McFaul, il fondatore del Centro, ha dichiarato:
“Se non fosse stato per i genitori che insistevano
dicendo che i vaccini sono responsabili della condizione
dei loro figli, non avremmo mai scoperto che lo
stabilizzatore del vaccino MMR e di qualche altro
vaccino è la gelatina idrolizzata, una sostanza composta
per il circa il 21% da glicina.
Appare chiaro che, basandosi su una scienza facilmente
verificabile, l’uso di quella forma di glicina scateni
uno sbilanciamento nei neurotrasmettitori aminoacidi
responsabili del tasso di assorbimento di alcune classi
di cellule in tutto il corpo.
E’ proprio questa
distruzione ad ampio spettro che risulterebbe nei
problemi sistemici che affliggono la mente e il corpo e
che vengono attualmente definiti come autismo
“classico”. L’utilizzo del nostro modello indica che
ciascuno dei disturbi nello spettro autistico (ASD) è
attribuibile a differenti distruzioni nell’omeostasi.”
Il Centro ora sta cercando di affiliarsi ai centri
accademici per fornire il proprio modello alla comunità
scientifica che avrà, a sua volta, le risorse per
studiare in maniera più approfondita questa scoperta e
diffonderla.
Tratto da: autismovaccini.splinder.com
Commento NdR: cosa causa l'alterazione della
omeostasi ?....specialmente i vaccini, c on le loro
sostanze tossiche, ne sono maggiormente responsabili, in
quanto alterano le funzioni cellulari e quindi
tissutali...con le conseguenze del caso !
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Catepsina D e l'apoptosi proteine correlate sono
elevati nel cervello dei soggetti autistici
By Sheikh AM, Li X, G Wen, Tauqeer Z, WT Brown, Malik M.
- Neuroscienze. 2010 gen 20; 165 (2) :363-70. EPub.
Articolo originale:
http://www.ncbi.nlm.nih.gov/pubmed/19854241
L'autismo è un grave disturbo neurologico caratterizzato
da problemi di comunicazione, abilità sociali e
comportamenti ripetitivi. Studi recenti suggeriscono che
i meccanismi di apoptosi può in parte contribuire alla
patogenesi di questo disturbo. Catepsina D è la proteasi
lisosomiali e predominante è abbondantemente espresso
nel cervello. Essa svolge un ruolo importante nella
regolazione dell'apoptosi cellulare e ha mostrato di
mediare l'apoptosi indotta dal fattore di necrosi
tumorale citochine (TNF)-alfa e interferone (IFN)-gamma.
In questo studio, abbiamo esaminato i livelli di
espressione di catepsina D nel cervello autistico.
Abbiamo scoperto che l'espressione della proteina
catepsina D è risultato significativamente aumentato
nella corteccia frontale, nelle cellule piramidali e
granello dell'ippocampo, e nei neuroni del cervelletto
nei soggetti autistici rispetto ai controlli. Inoltre,
abbiamo scoperto che l'espressione della proteina
anti-apoptotica Bcl-2 era significativamente diminuito,
mentre caspasi-3, un boia critico di apoptosi, è stato
aumentato nel cervelletto di soggetti autistici. In
precedenza i nostri studi hanno dimostrato che Bcl-2 è
diminuita e il Akt-Bcl-2 BDNF percorso è compromesso
nella corteccia frontale dei soggetti autistici, che ha
suggerito che l'apoptosi aumentata possono essere
coinvolti nella patogenesi dell'autismo.
La nostra scoperta attuale di diminuzione delle Bcl-2 e
una maggiore capase-3 nel cervelletto di soggetti
autistici inoltre sostiene questa proposta. Inoltre, il
ritrovamento di catepsina D aumentato nel cervelletto di
soggetti autistici suggerisce che, attraverso la sua
regolazione dell'apoptosi, l'attività della catepsina D
alterato nel cervello autistico può svolgere un ruolo
importante nella patogenesi dell'autismo.
vedi: Cellule
+ Meccanismo dei danni dei
Vaccini - Polio dai vaccini
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Leucociti (globuli bianchi) del sangue
periferico, di produzione di BDNF in seguito a
stimolazione mitogene a esordio precoce e autismo
regressivo
By
Enstrom A et al. - American Journal of Biochimica e
Biotecnologie 4 (2): 121-129, 2008
http://www.scipub.org/fulltext/ajbb/ajbb42121-129.pdf
Il
Brain-derived neurotrophic factor (BDNF) è
fondamentale per la differenziazione neuronale e lo
sviluppo sinaptico. BDNF è anche implicata nello
sviluppo di disturbi psicologici inclusi depressione,
disturbo bipolare e schizofrenia.
In precedenza, elevati livelli di BDNF sono stati
osservati in campioni di sangue neonatale dei neonati
che sono stati successivamente diagnosticati con autismo
rispetto ai bambini che si sono sviluppati normalmente,
suggerendo che il BDNF potrebbero essere coinvolto nello
sviluppo di autismo.
BDNF viene prodotto dalle
cellule
microgliali attivate nel
cervello, un
fenotipo cellulare che dispone di diverse parti con
macrofagi periferici, suggerendo un ruolo importante per
il sistema
immunitario nella produzione di BDNF.
Abbiamo ipotizzato che sotto la stimolazione mitogenica,
le cellule mononucleate del sangue periferico ottenute
da bambini con autismo possa aver alterato la produzione
di BDNF rispetto agli altri bambini di pari età con i
soggetti di controllo. Inoltre, abbiamo esaminato le
differenze tra la produzione di BDNF in classico /
autismo ad esordio precoce e bambini che erano una forma
di autismo regressivo.
Mostriamo qui che i livelli plasmatici dei livelli di
BDNF sono aumentati nei bambini con autismo, soprattutto
nei soggetti ad esordio precoce dell'autismo. Inoltre,
ai sensi mitogenica stimolazione con PHA e LPS, la
produzione di BDNF è significativamente aumentata nei
bambini con autismo rispetto ai soggetti con sviluppo
normale.
Tuttavia, la stimolazione con tossoide tetanico si
traduce in una diminuzione della risposta nei
bambini
con autismo.
Questi dati suggeriscono che la produzione
di cellule immunitarie derivate di BDNF potrebbero
essere una fonte importante per l'aumento del BDNF che
viene rilevato in alcuni soggetti con autismo.
Come un fattore neurotrofico prodotto da cellule del
sistema immunitario, BDNF potrebbe contribuire a
spiegare il ruolo del sistema immunitario nella
manutenzione neurosviluppo e cellule neuronali, che
possono essere sregolati nell'autismo.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Analisi
nella famiglia, delle classi e sottoclassi di
immunoglobuline nei bambini con disturbo autistico
By Spiroski M et al. - Istituto di Immunobiologia e
Genetica Umana, Facoltà di Medicina, 1109 Skopje, PO Box
60, Macedonia. - Bosn J Med Sci di base. 2009 Nov; 9 (4)
:283-9.
Il disturbo Autistico è un
disordine dello sviluppo neurologico grave
caratterizzata da una triade di menomazioni
dell'interazione sociale reciproca, la comunicazione
verbale e non verbale, e un modello di ripetitivi
stereotipati attività, comportamenti e interessi.
Ci
sono linee di forza di prove che suggeriscono che il
sistema immunitario ha un ruolo importante nella
patogenesi del disturbo autistico.
Lo scopo di questo studio era quello di analizzare la
concentrazione plasmatica quantitativa delle classi di
immunoglobuline, e sottoclassi di pazienti autistici e
delle loro famiglie.
L'indagine è stata effettuata a posteriori in 50 persone
con disturbo autistico nella Repubblica di Macedonia.
Infantile disturbo autistico è stato diagnosticato dal
DSM-IV e ICD-10 criteri. classi di immunoglobuline del
plasma (IgM, IgA e IgG) e sottoclassi (IgG1, IgG2, IgG3
e IgG4) sono stati determinati utilizzando Nefelometro
Analyzer BN-100. confronti multipli per la variabile di
IgA hanno mostrato differenze statisticamente
significative tra le tre coppie: autistici maschi dai
padri (p = 0,001), autistici femminile dalle madri (p =
0.008), così come sorelle sani dai padri (p = 0.011) .
Differenze statisticamente significative tra tre gruppi
per quanto riguarda disturbo autistico (persone con
Disturbo Autistico, padre / madre di una persona con
disturbo autistico, e il fratello / sorella),
indipendentemente dal sesso appartiene a IgA, IgG2 e
variabili IgG3. confronti multipli per la variabile di
IgA hanno mostrato differenze statisticamente
significative tra i bambini con disturbo autistico da
padri e madri (p <0,001), ed i fratelli e le sorelle
sani da padri e madri (p <0,001).
Confronto tra bambini sani e bambini affetti da disturbi
autistici della stessa famiglia dovrebbero essere
testati per classi e sottoclassi di immunoglobuline, al
fine di evitare le differenze tra le generazioni.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Ridotti
livelli di immunoglobuline nei bambini con autismo si
correla con sintomi comportamentali
By Heuer L et al. - Università di California a Davis -
Autismo Ris. 2008 Ott, 1 (5) :275-83.
Articolo originale:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663897/pdf/nihms97987.pdf
OBIETTIVI:
Per analizzare se i livelli plasmatici degli anticorpi
in bambini con autismo o ritardo nello sviluppo (DD)
differiscono da quelli con sviluppo tipico come un
indicatore della funzione immunitaria e di correlare i
livelli di anticorpi con la severità dei sintomi
comportamentali. METODI: plasma è stato raccolto da
bambini con disturbo autistico (UA; n = 116), DD, ma non
autistici (n = 32), il disturbo dello spettro autistico,
ma non completa l'autismo (n = 27), e di pari età in
genere in via di sviluppo (TD) controlli (n = 96).
I campioni sono stati analizzati per livelli sistemici
di immunoglobuline (IgG, IgM, IgA e IgE) da
enzima-collegata dell'immunosorbente. I soggetti con
autismo sono stati valutati usando l'Autism Diagnostic
Observation Schedule e la Autism Diagnostic
Interview-Revised, e tutti i soggetti sono stati
valutati sul comportamento aberrante Checklist (ABC) dai
genitori. punteggi numerici per ciascuna delle
sottoscale ABC così come il punteggio totale sono quindi
stati correlati con i livelli di Ig.
RISULTATI: I bambini con AU hanno un livello
significativamente ridotto di IgG nel plasma (5,39 + /
-0,29 mg / mL) rispetto al TD (7,72 + / -0,28 mg / mL, P
<0,001) e dei bambini DD (8,23 + / -0,49 mg / mL, P
<0,001). I bambini con autismo ha avuto anche un ridotto
livello di plasma IgM (0.670.06 mg / mL) rispetto a TD
(0,79 + / -0,05 mg / mL, P <0,05). Ig livelli erano
correlati negativamente con i punteggi di ABC per tutti
i bambini (IgG: r =- 0,334, p <0.0001; IgM: r =- 0,167,
p = 0,0,285 mila).
CONCLUSIONE: I bambini con AU hanno ridotto
significativamente i livelli plasmatici di IgG e IgM
rispetto sia DD e controlli TD, suggerendo un difetto di
fondo della funzione immunitaria. Questa riduzione di
specifici livelli di Ig è correlata con la gravità del
comportamento, in cui i pazienti con i punteggi più alti
nella batteria comportamento hanno i livelli più ridotti
di IgG e IgM.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Risposta
immunitaria allergica nella sindrome di Asperger
By Magalhães ES, Pinto-Mariz F,
Bastos-Pinto S, Pontes AT, Prado EA, deAzevedo LC. - J
Neuroimmunol. 2009 Nov 30; 216 (1-2) :108-12.
Articolo originale:
http://www.ncbi.nlm.nih.gov/pubmed/19840888
La sindrome di Asperger è un sottogruppo di autismo
caratterizzato da deficit sociali senza ritardo del
linguaggio, e ad alte prestazioni cognitive. La natura
biologica dell'autismo è ancora sconosciuta, ma ci sono
prove controverse associando uno squilibrio immunitario
e autismo. risultati clinici, comprese storia familiare
atopica, i livelli sierici di IgE così come le prove
cutanee hanno mostrato che l'incidenza di atopia è stata
maggiore nel gruppo di Asperger rispetto ai controlli
sani. Questi risultati suggeriscono che l'atopia è
frequente in questo sottogruppo di autismo che implica
che l'infiammazione allergica possa essere un elemento
importante nella sindrome di Asperger.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
BIBLIOGRAFIA
http://healthimpactnews.com/2014/the-vaccine-autism-cover-up-how-one-doctors-career-was-destroyed-for-telling-the-truth/
Vaccini
e rigonfiamento cerebrale
Iwasa S, "Rigonfiamento del cervello in topi causato dal vaccino
anti-pertosse", Jpn J Med Sci Biol, 1985, 38(2):53-65
Mathur R, Kumari S, "-Fontanella protuberante- a seguito di vaccino
triplo", Indian Pediatr, giugno 1981; 18(6): 417-418
Barry W, Hatcher G, "-Fontanelle protuberanti- in neonati senza
meningite", Arch Dis Child, aprile 1989; 64(4): 635-636
Shendurnikar N, "-Fontanella protuberante- a seguito di vaccino DPT",
Indian Pediatr, nov. 1986; 23(11): 960
Gross TP, Milstien JB, Kuritsky JN, "-Fontanella protuberante- a seguito di
vaccinazione anti-difterica- tetano- pertosse e vaccino tetano- difterica", J
Pediatr, marzo 1989;114(3):423-425
Jacob J, Mannino F, "Aumento di pressione intracraniale a seguito di vaccino
anti- difterica, tetano e pertosse", Am J Dis Child, feb. 1979; 133(2):217-218
Dugmore, WN, "Edema bilaterale del polo posteriore: ipersensibilità al
vaccino Alavac P", Br J Ophthalmol, dic. 1972, 55:848-849
Altra Bibliografie su Autismo dai Vaccini
Abell
F, Krams M, Ashburner J, Passingham R, Friston K, Frackowiak R, Happé
F, Frith C, Frith U, ‘The neuroanatomy of autism: a voxel-based whole
brain analysis of structural scans’, NeuroReport, June 1999,
Vol. 10, No. 8, 1647-1651 |
|
Adams
CR, Ziegler DK, Lin JT, ‘Mercury intoxication simulating amyotrophic
lateral sclerosis’, JAMA 1983; 250:642-643. |
|
Al-Balaghi
S, Möller E, Möller G, Abedi-Valugerdi M, ‘Mercury induces
polyclonal B cell activation, autoantibody production and renal immune
complex deposits in young (NZB x NZW) F1 hybrids’, Eur J Immunol,
July 1996, 26(7):1519-1526 |
|
Alberti
A, Pirrone P, Elia M, Waring RH, Romano C, ‘Sulphation deficit in
“low-functioning” autistic children: a pilot study’, Biol
Psychiatry 1999 Aug 1; 46(3):420-424 |
|
Altman
DG, Bland JM, ‘Absence of evidence is not evidence of absence’, Br
Med J, 1995;311:485 |
|
American
Academy of Pediatrics and US Public Health Service, July 8, 1999,
'Thimerosal, a Mercury-containing Preservative Used in Some Vaccines' |
|
American
Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Washington D.C., 1994 |
|
Amin-Zaki
L, Majeed MA, Clarkson TW, Greenwood MR, ‘Methylmercury poisoning in
Iraqi children: clinical observations over two years’, British
Medical Journal 1978 March 1, 613-616 |
|
Amin-Zaki
L, Majeed MA, Elhassani SB, Clarkson TW, Greenwood MR, Doherty RA,
‘Prenatal Methylmercury Poisoning’, American Journal of the
Disabled Child, 1979 Feb 133:172-177 |
|
Amin-Zaki,
L, Elhassani S, Majeed MA, Clarkson TW, Doherty RA, Greenwood M,
‘Intra-uterine methylmercury poisoning in Iraq’, Pediatrics
1974 Nov 54:5587-595 |
|
Anuradha
B, Rajeswari M, Varalakshmi P, ‘Degree of peroxidative status in
neuronal tissues by different routes of inorganic mercury
administration’, Drug Chem Toxicol 1998 Feb;21(2):47-55 |
|
Applied
Toxicology,
1992 Apr;12(2):79-84 |
|
ARI
Newsletter,
review, 'Long term follow-up: early intervention effects lasting', 1993
7(1):1&6 |
|
Aronow
R, Fleischmann L ,‘Mercury Poisoning in Children’, Clinical
Pediatrics, 1976 Oct, Vol.15, No.10, 936-945 |
|
Arvidsson
T, Danielsson B, Forsberg P, Gillberg C, Johansson M, Kjellgren G, ‘
Autism in 3-6 year old children in a suburb in Göteborg, Sweden’, Autism,
November 1997, Vol. 1, No. 2, 163-173 |
|
Aschner
M, Aschner JL, ‘Mercury Neurotoxicity: Mechanisms of Blood-Brain
Barrier Transport’, Neuroscience & Behavioral Reviews,
1990, Vol. 14, 169-176 |
|
Aschner
M, Lorscheider FL, Cowan KS, Conklin DR, Vimy MJ, Lash LH,
‘Methallothionein induction in fetal rat brain and neonatal primary
astrocyte cultures by in utero’, Brain Res, Dec 5;
778(1):222-232 |
|
Ashour
H, Abdel-Rahman M, Khodair A., 1993 ‘The mechanism of methyl mercury
toxicity in isolated rat hepatocytes’, Toxicology Letters 1993
Jul;69(1):87-96 |
|
Atchison
WD and Hare MF, ‘Mechanisms of methylmercury-induced neurotoxicity’,
FASEB Journal 1994 Jun;8(9):622-629 |
|
Atchison
WD, Joshi U, Thornburg JE, ‘Irreversible Suppression of Calcium Entry
into Nerve Terminals by Methylmercury’, The Journal of Pharmacology
and Experimental Therapeutics, 1986, Vol. 238, No. 2, 618-624 |
|
Aukrust
P, et al, ‘Decreased levels of total and reduced glutathione in CD4+
lymphocytes in common variable immunodeficiency are associated with
activation of the tumor necrosis factor system: possible
immunopathogenic role of oxidative stress’, Blood, 1995,
86.4.1383-1391 |
|
Aukrust
P, et al, 'Persistent activation of the tumor necrosis factor system in
subgroup of patients with common variable immunodeficiency - possible
immunological and clinical consequences’, Blood, 1996,
97.2.674-681 |
|
Aylward
EH, Minshew NJ, Goldstein G, Honeycutt NA, Augustine AM, Yates KO, Barta
PE, Pearlson GD, 'MRI volumes of amygdala and hippocampus in
non-mentally retarded autistic adolescents and adults', Neurology
1999 Dec 10;53(9):2145-50 |
|
Bachevalier
J, 'Brief Report: Medial Temporal Lobe and Autism: A Putative Animal
Model in Primates', Journal of Autism and Developmental Disorders,
1996;26(2):217-220 |
|
Bachevalier
J, 'Medial Temporal Lobe Structures: a Review of Clinical and
Experimental Findings', Neuropsychologia, 1994;32:627-648 |
|
Bagenstose
LM, Salgame P, Monestier M, ‘Mercury-induced autoimmunity in the
absence of IL-4’, Clin Exp Immunol, Oct 1998, 114(1):9-12 |
|
Bagenstose
LM, Salgame P, Monestier M, ‘Murine mercury-induced autoimmunity: a
model of chemically related autoimmunity in humans’, Immunol Res,
1999, 20(1):67-78 |
|
Bailey
A, Phillips W, Rutter M, ‘Autism: Towards an Integration of Clinical,
Genetic, Neuro-psychological, and Neurobiological Perspectives’, J
Child Psychol Psychiatry 1996 Jan; 37(1): 89-126. |
|
Bailey
A, Luthert P, Dean A, Harding B, Janota I, Montgomery M, Rutter M,
Lantos, 'A clinicopathological study of autism', Brain 1998
May;121 ( Pt 5):889-905 |
|
Bakir
F, Damluji SF, Amin-Zaki L,
Murtadha M, Khalidi A, Al-Rawi NY, Tikrit S, Dhahir HI, Clarkson TW,
Smith JC, Doherty RA, ‘Methylmercury poisoning in Iraq’, Science,
July 1973, 181;230-241 |
|
Baranek
G, 'Autism During Infancy: A
Retrospective Video Analysis of Sensory-Motor and Social Behaviors and
9-12 Months of Age', Journal of Autism and Developmental Disorders,
1999, Vol. 29, No. 3, pp. 213-224 |
|
Baron-Cohen
S, Ring HA, Wheelwright S, Bullmore ET, Brammer MJ, Simmons A, Williams
SC, 'Social intelligence in the normal and autistic brain: an fMRI
study', Eur J Neuroscience 1999 Jun;11(6):1891-8 |
|
Baron-Cohen
S, Leslie A, Frith U, ‘Does the autistic child have a ‘theory of
mind’?’, Cognition, 1985, No. 21, pp. 37-46 |
|
Baron-Cohen
S, Allen J, Gillberg C, 'Can autism be detected at 18 months: the
needle, the haystack, and the CHAT', Br. J. Psychiatry,
1992;161:839-843 |
|
Baron-Cohen
S, Tager-Flusberg H, Cohen D, Understanding Other Minds: Perspectives
from Autism, Oxford: Oxford University Press, 1993 |
|
Barregard
L, Sallsten G, Conradi N, ‘Tissue levels of mercury determined in a
deceased worker after occupational exposure’, Int Arch Occup
Environ Health 1999 May;72(3):169-173 |
|
Bartolome
J, Whitmore WL, Seidler FJ, Slotkin TA 1984 ‘Exposure to methylmercury
in utero: effects on biochemical development of catecholamine
neurotransmitter systems’, Life Sciences 1984 Aug
6;35(6):657-670 |
|
Bauman
ML, Kemper TL, 'Neuroanatomical observations of the brain in autism', in
Bauman & Kemper, eds, The Neuroanatomy of Autism, The Johns
Hopkins University Press |
|
Bauman
ML and Kemper TL, Journal of Experimental Neurology, 1988 47:369 |
|
Bauman
M, Kemper TL, 'Histoanatomic observations of the brain in early
infantile autism', Neurology, 1985;35:866-874 |
|
Bernabei
P, Camaioni L, Levi G, ‘An evaluation of early development in children
with autism and pervasive developmental disorders from home movies:
preliminary findings’, Autism, September 1999, Vol. 2, No. 3,
243-258 |
|
Bettleheim
B, 'A letter from Bruno Bettleheim', Autism Research Review
International, 1989, Vol
3, No. 3, p. 6 |
|
Bidet
B, Leboyer M, Descours B, Bouvard MP, Benveniste J, ‘Allergic
sensitization in infantile autism’ (letter), Journal of Autism and
Developmental Disorders, June 1993, Vol. 23, No. 2, pp. 419-420 |
|
Binstock
T, 'Fragile X and the amygdala: cognitive, interpersonal, emotional, and
neuroendocrine considerations', Dev Brain Dysfunction 1995
8:199-217 |
|
Bonnet
JJ, Benmansour S, Amejdki-Chab N, Costentin J, ‘Effect of CH3HgCl and
several transition metals on the dopamine neuronal carrier; peculiar
behaviour of Zn2+’, Eur J Pharmacol 1994 Jan 1;266(1)87-97 |
|
Bouilleret
V, Boyet S, Marescaux C, Nehlig A, ‘Mappingof the progressive
metabolic changes occurring during the development of hippocampal
sclerosis in a model of mesial temporal lobe epilepsy’, Brain
Research, 2000, 952:255-262 |
|
Brenner
RP and Snyder RD, ‘Late EEG finding and clinical status after organic
mercury poisoning’, Archives of Neurology 1980 May;
37(5):282-284 |
|
Bristol
M, Cohen D, Costello E, Denckla M, Eckberg T, Kallen R, Kraemer H, Lord
C, Maurer R, McIlvane W, Minshew N, Sigman M, Spence M, 'State of the
Science in Autism: Report to the National Institutes of Health' , Journal
of Autism and Developmental Disorders, 1996, Vol. 26, No. 2, pp.
121-157 |
|
Bryson
SE, ‘Brief Report: Epidemiology of Autism’, Journal of Autism and
Developmental Disorders, 1996, Vol. 26, No. 2, 165-167 |
|
Bryson
SE, Smith IM, Eastwood D, 'Obstetrical suboptimality in autistic
children', J Am Acad Child Adolesc Psychi, 1988;27(4)418-22 |
|
Bulleit
RF, Cui H, ‘Methylmercury antagonizes the survival-promoting activity
of insulin-like growth factor on developing cerebellar granule
neurons’, Toxicol Appl Pharmacol 1998 Dec;153(2):161-168. |
|
Cagiano
R, De Salvia MA, Renna G, Tortella E, Braghiroli D, Parenti C, Zanolie
P, Baraldi M, Annau Z, Cuomo V, ‘Evidence that exposure to methyl
mercury during gestation induces behavioral and neurochemical changes in
offspring of rats’, Neurotoxicol Teratol 1990 Jan-Feb;12(1):23-28 |
|
Camerino
, Cassitto M, 'Behavior of Some Psychological Parameters of a Population
of a Hg Extraction Plant', Journal of Clinical Toxicology, 1981,
Vol. 18 (11), pp. 1299-1309 |
|
Capps
L, Kehres J, Sigman M, 'Conversational abilities among children with
autism and children with developmental delays', Autism, 1998 Dec;2(4):325-44 |
|
Carlsson
ML, ‘Hypothesis: is infantile autism a hypoglutamatergic disorder?
Relevance of glutamate - serotonin interactions for pharmacotherapy’, Journal
of Neural Transmitters 1998 105(4-5):525-535 |
|
Carlsson
ML, Martin P, Nilsson M, Sorensen SM, Carlsson A, Waters S, Waters N,
‘The 5-HT2A receptor antagonis M100907 is more effective in
counteracting NMDA antagonist- than dopamine agonist-induced
hyperactivity in mice’, J Neural Transm 1999; 106(2):123-129 |
|
Carpenter
PK, Morris D, ‘Association of acrocyanosis with Asperger’s
syndrome’, Journal of Mental Deficiency Research, 1990, 34, pp.
97-90 |
|
CDC,
‘Recommendations Regarding the Use of Vaccines That Contain Thimerosal
as a Preservative’, MMWR November 5, 1999 / 48(43); 996-998 |
|
CDC,
‘Thimerosal in vaccines: a joint statement of the Amercian Academy of
Pediatrics and the Public Health Service’, MMWR Morb Mortal Wkly
Rep 1999 July 9; 48(26):563-565 |
|
CDC,
'Record Immunization Rate, 80% of Kids Getting Vaccinated', Associated
Press, September 23, 1999 |
|
Cesaroni
L, Garber M, 'Exploring the experience of autism through firsthand
accounts', Journal of Autism and Developmental Disorders, 1991
Sep;21(3):303-13 |
|
Chapman
AG, Elwes RD, Millan MH, Polkey CE, Meldrum BS, 'Role of Glutamate and
Aspartate in Epileptogenesis; Contribution of Microdialysis Studies in
Animal and Man', Epilepsy Res Suppl, 1996, Vol. 12, pp. 239-246 |
|
Cheek
DB, 'Acrodynia', in Brennemann's Practice of Pediatrics, Chapter
17D, from Pink Disease website,
www.users.bigpond.com/difarnsworth/pcheek42.htm |
|
Chodorowski
Z, Sein Anand J, Nowicki A, Galant K, ‘Subcutaneous self-injection and
oral self-administration of metallic mercury - case report’, Przegl
Lek 1997;54(10):759-762 |
|
Chu
CC, Huang CC, Ryu SJ, Wu TN, ‘Chronic inorganic mercury induced
peripheral neuropathy’, Acta Neurology Scandanavia 1998 Dec;98(6):461-465 |
|
Chugani
DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee J, Chugani HT,
‘Developmental Changes in Brain Serotonin Synthesis Capacity in
Autistic and Nonautistic Children’, Ann Neurol 1999; 45: |
|
Church
C, Coplan J, 'The High Functioning Autistic Experience: Birth to Preteen
Years', Journal of Pediatric Health Care, 1995, Vol. 9, pp.22-29 |
|
Clarke
D, Baxter M, Perry D, Prasher V, 'The diagnosis of affective and
psychotic disorders in adults with autism: seven case reports', Autism,
1999 Jun;3(2):149-164 |
|
Clarkson
TW, ‘Mercury: Major Issues in Environmental Health’, Environmental
Health Perspectives vol. 100, pp. 31-38, 1992 |
|
Clarkson,
T. 1997 ‘The Toxicology of Mercury’, Critical Reviews in Clinical
Laboratory Sciences, 34(3): 369-403 (1997) |
|
Clarkson,
TW, ‘Mercury - an element of mystery’, The New England Journal of
Medicine 1990 Oct 18 |
|
Clarkson,T.W,
1993, 'Molecular and ionic mimicry of toxic metals', Annu. Rev.
Pharmacol. Toxicol. 32:545-571 |
|
Cloarec
S, Deschenes G, Sagnier M, Rolland JC, Nivet H, ‘Arterial hypertension
due to mercury poisoning: diagnostic value of captopril’, Arch
Pediatr 1995 Jan;2(1):43-46 |
|
Close
AH, Guo TL, Shenker BJ, ‘Activated human T lymphocytes exhibit reduced
susceptibility to methylmercury chloride-induced apoptosis’, Toxicol
Sci 1999 May;49(1):68-77 |
|
Coccini
T, Randine G, Candura SM, Nappi RE, Prockop LD, Manzo L, ‘Low-Level
Exposure to Methylmercury Modifies Muscarinic Cholinergic Receptor
Binding Characteristics inRat Brain and Lymphocytes: Physiologic
Implications and New Opportunities in Biologic Monitoring’, Environ
Health Perspect, 2000 Jan;108(1):29-33 |
|
Coleman
M, ‘Nutritional treatments currently under investigation in autism’,
Clinical Nutrition, Sept/Oct 1989, Vol. 8, No. 5, pp. 210-212 |
|
Comi
AM, Zimmerman A et al, 'Familial clustering of autoimmune disorders and
evaluation of medical risk factors in autism', Journal of Child
Neurology, 1999, Vol. 14, pp. 388-394 |
|
Connolly
AM, et al, ‘Serum autoantibodies to brain in Landau-Kleffner variant,
autism, and other neurologic disorders’, Journal of Pediatrics,
May 1999, Vol. 134, No. 5, pp. 607-613 |
|
Cook
EH, ‘Autism: review of neurochemical investigation’, Synapse,
1990, 6:292-308 |
|
Courchesne
E, et al,‘More evidence links autism, cerebellar defects’, reviewed
in Autism Research Review International, 1994, Vol. 8, No. 2, pp.
1&7 |
|
Courchesna
E, Press GA, Young-Courchesne R, 'Parietal lobe abnormalities detected
with MR in patients with infantile autism', AJR Am J Roentgenol
1993 Feb;160(2):387-93 |
|
Courchesne
E, 'Brainstem, cerebellar and limbic neuroanatomical abnormalities in
autism', Current Opin Neurobiol 1997 Apr;7(2):269-78 |
|
Courchesne
E, Saitoh O, Townsend J, Yeung-Courchesne R, Lincoln AJ, Schreibman L,
Haas RH, Press GA, 'Cerebellar Abnormalities in Autism: New Evidence and
A Re-Analysis of Old Evidence', pp. 211-214 |
|
Courchesne
E, Yeung-Courchesne R, Elmasian R, Grillon C, 'Pathophysiologic findings
in non-retarded autism and receptive developmental language disorder', Journal
of Autism and Developmental Disorders, 1989; 19:1-17 |
|
Courchesne
E, Yeung-Courchesne R, Press GA, Hesselink JR, Jernigan TL,
‘Hypoplasia of cerebellar vermal lobules VI and VII in autism’, New
England Journal of Medicine 1988 318:1349-1354 |
|
Courchesne
E, Yeung-Courchesne R, Press GA, Hesselink JR, Jernigan TL,
‘Hypoplasia of cerebellar vermal lobules VI and VII in autism’, New
England Journal of Medicine, May 26, 1998; pp. 1349-1354 |
|
Courchesne
E, reported in The New York Times, 'Science Times' section, Dec
28, 1999, by Blakeslee S |
|
Cox
NH, Forsyth A, ‘Thiomersal allergy and vaccination reactions’, Contact
Dermatitis 1988:18:229-233 |
|
Creel
DJ, Crandall AS, Pingree C, Ritvo ER, 'Abnormal electroretinograms in
autism', Clinical Vision Science 1989 4(1):85-88 |
|
Cuomo
V, Ambrosi L, Annau Z, Cagiano R, Brunello N, Racagni G 1984,
‘Behavioral and neurochemical changes in offspring of rats exposed to
methyl mercury during gestation’, Neurobehavior Toxicology Teratol
1984 May-June;6(3):249-254 |
|
D’Eufemia
P, Celli M, Finocchiaro R, Pacifico L, Viozzi L, Zaccagnini M, Cardi E,
Giardini O, ‘Abnormal intestinal permeability in children with
autism’, Acta Pædiatr 1996:85:1076-1079 |
|
D’Eufemia
P, Finocchiaro R, Celli M, Viozzi L, Monteleone D, Giardini O, ‘Low
serum tryptophan to large neutral amino acids ratio in idiopathic
infantile autism’, Biomed. &
Pharmacother.,
1995, Vol. 49, pp. 288-292 |
|
Dales
LD, ‘The Neurotoxicity of Alkyl Mercury Compounds’, American journal
of Medicine, August 1972, Vol. 53, 219-232 |
|
Dally
A, 'The Rise and Fall of Pink Disease', Wellcome Institute for the
History of Medicine, 1997, available at
www.users.bigpond.com/difarnsworth |
|
Dathan
JG, 'Pink Disease-Ten Years After (The Epilogue), British Medical
Journal, 1965, Vol 1, pp. 1181-1182 |
|
Dave
V, Mullaney KJ, Goderie S, Kimelberg HK, Aschner M, ‘Astrocytes as
mediators of methylmercury neurotoxicity: effects on D-aspartate and
serotonin uptake’, Dev Neurosci 1994;16(3-4):222-231 |
|
Davis
LE, Kornfeld M, Mooney HS, Fiedler KJ, Haaland KY, Orrison WW,
Cernichiari E, Clarkson TW, ‘Methylmercury poisoning: long term
clinical, radiological, toxicological, and pathological studies of an
affected family’, Annals of Neurology 1994 35:6 680-688 |
|
Dawson
G, ‘Brief Report: Neuropsychology of Autism: A Report on the State of
the Science’, Journal of Autism and Developmental Disorders,
1996, Vol. 26, No. 2, 179-184 |
|
Deb
S and Thompson B, ‘Neuroimaging in autism’, British Journal of
Psychiatry 1998 Oct 173:299-302 |
|
DelGiuidce-Asch
G, Hollander E, ‘Altered immune function in autism’, CNS
Spectrums: International Journal of Neuropsychiatric Medicine, 1997,
2:61-68 |
|
DeLong
GR, ‘Autism: new data suggest a new hypothesis’, Neurology,
March 1999, Vol. 52, No. 5, pp. 911-916 |
|
Deutsch
S, Campbell M, Sachar E, Green W, David R, ‘Plasma growth hormone
response to oral L-dopa in infantile autism’, Journal of Autism and
Developmental Disorders, June 1985, Vol. 15, No. 2, pp. 205-212 |
|
Deyab
P, Gochfeldbc M, Reuhlabca K, 'Developmental Methylmercury
Administration Alters Cerebellar PSA-NCAM expression and Golgi
sialyltransferase Activity', 1999 |
|
Diner
Barry, M.D., Brenner Barry, M.D.,Toxicity, Mercury, 1998 |
|
Edelson
MG, Edelson SM, Jung S, ‘Assessing the Intelligence of Individuals
with Autism: A Cross-Cultural Replication of the Usefulness of the
TONI’, Focus on Autism and Other Developmental Disabilities,
Winter 1998, Vol. 13, No. 4, 221-227 |
|
Edelson
MG, Schubert DT, Edelson SM, ‘Factors Predicting Intelligence Scores
on the TONI in Individuals with Autism’, Focus on Autism and Other
Developmental Disabilities, Spring 1998, Vol. 13, No. 1, 17-26 |
|
Edelson
SB, Cantor DS, ‘Autism: xenobiotic influences’, Toxicol Ind
Health, 1998 Jul-Aug;14(4):553-563 |
|
Egan,
William M. 1999 ‘Thimerosal in Vaccines’, presentation to the FDA,
September 14, 1999 |
|
Eisenmayer
R et al, 'Delayed language onset as a predictor of clinical symptoms in
pervasive developmental disorders', Journal of Autism and
Developmental Disorders, 1998 Dec 28(6):527-33 |
|
El-Fawal
HA, Waterman SJ, De Feo A, Shamy MY, ‘Neuroimmunotoxicology: Humoral
Assessment of Neurotoxicity and Autoimmune Mechanisms’, Environ
Health Perspect 1999 Oct;107(Suppl 5):767-775 |
|
Elferink
JG Thimerosal: a versatile sulfhydryl reagent,calcium mobilizer, and
cell function-modulating agent.Gen Pharmacol 1999 Jul;33(1):1-6 |
|
Environmental
Protection Agency (EPA), lead authors - Hassett-Sipple B, Swartout J,
Schoeny R, 'Vol. V - Health Effects of Mercury and Mercury Compounds', Mercury
Study Report to Congress, December 1997 |
|
Ernst
M, Zametkin AJ, Matochik JA, Pascualvaca D, Cohen RM, 'Low medial
prefrontal dopaminergic activity in autistic children', Lancet
1997 Aug 30;350(9078):638 |
|
Eto
K, Takizawa Y, Akagi H, Haraguchi K, Asano S, Takahata N, Tokunaga H,
‘Differential diagnosis between organic and inorganic mercury
poisoning in human cases - the pathologic point of view’, Toxicol
Pathol 1999 Nov-Dec;27(6):664-671 |
|
Fagala
GE,Wigg CL, ‘Psychiatric Manifestions of Mercury Poisoning’, J.
Am. Acad. Child. Adolesc. Psychiatry, March 1992,
31(2):306-311. |
|
Fagan
DG, Pritchard JS, Clarkson TW, Greenwood MR, ‘Organ mercury levels in
infants with omphaloceles treated with organic mercurial antiseptic’, Archives
of Disease in Childhood, 1977 52:962-964 |
|
Farnsworth
D, ‘Pink Disease Survey Results’, Pink Disease Support Group Site,
1997
www.users.bigpond.com/difarnsworth |
|
Faro
LR, Duran R, do Nascimento JL, Alfonso M, Picanco-Diniz CW, ‘Effects
of methyl mercury on the in vivo release of dopamine and its acidic
metabolites DOPAC and HVA from Striatum of rats’, Ecotoxicol
Environ Saf 1997 Nov;38(2):95-98 |
|
Faro
LRF, Nascimento JLM do, Alfonso M, Duran R, ‘Acute Administration of
Methylmercury Changes In Vivo Dopamine Release from Rat
Striatum’, Bulletin of Environmental Contamination Toxicology,
1998 60:632-638 |
|
FDA,
HHS, ‘Mercury Containing Drug Products for Topical Antimicrobial
Over-the-Counter Human Use; Establishment of a Monograph’, Federal
Register, January 5 1982, Vol. 47, No. 2, 436-442 |
|
FDA,
'Mercury Compounds in Drugs and Food', 98N-1109, November 16, 1999 |
|
Feldman
R, 'Neurological Manifestations of Mercury Intoxication', Journal of
Occupational Neurology, 1982, Vol. 66, pp. 201-209 |
|
Filipek
P, Accardo P, Baranek G, Cook E, Dawson G, Gordon B, Gravel J, Johnson
C, Kallen R, Levy S, Minshew N, Prizant B, Rapin I, Rogers S, Stone W,
Teplin S, Tuchman R, Volkmar F, 'The Screening and Diagnosis of Autistic
Spectrum Disorders', Journal of Autism and Developmental Disorders,
1999, Vol. 29, No. 6, pp. 439-484 |
|
Finegan
J, Quarrington B, 'Pre-, peri-, and neonatal factors and infantile
autism', J Child Psychol Psychi, 1979; 20.119-128 |
|
Florentine
MJ and Sanfilippo II DJ, ‘Grand Rounds: Elemental mercury
poisoning’, Clinical Pharmacy 1991 Mar 10:213-221 |
|
Fombonne
E, Rogé B, Claverie J, Courty S, Frémolle J, ‘Microcephaly and
Macrocephaly in Autism’ Journal of Autism and Developmental
Disorders, 1999, Vol. 29, No. 2, 113-119 |
|
Food
and Drug Administration, 1997 ‘Status of Certain Additional
Over-the-Counter Drug Category II and III Active Ingredients’, Docket
Nos. 75N-183F, 75N-183D, and 80N-0280, October 19,1998 |
|
Fournier
L, Thomas, G, Garnier, R, Buisine, A, Houze, P, Pradier, F, and Dally, S
1988, ‘2,3-Dimercaptosuccinic Acid Treatment of Heavy Metal Poisoninig
in Humans’, Medical Toxicology 3: 499-505 (1988) |
|
Frackelton
JP, Christensen RL, ‘Mercury Poisoning and Its Potential Impact on
Hormone Regulation and Aging: Preliminary Clinical Observations Using a
New Therapeutic Approach’, Journal of Advancement in Medicine
1998 Spring 11(1):9-25 |
|
Fredriksson
A, Dencker L, Archer T, Danielsson BGR, ''Prenatal coexposure to
metallic mercury vapour and methylmercury produce interactive
behavioural changes in adult rats', Neurotoxicol Teratol 1996
19(2):129-134 |
|
Fuchs
J, Packer L, Zimmer G, Lipoic Acid in Health and Disease, Marcel
Dekker, Inc., 1997 |
|
Fuchs
J, Schöfer H, ‘Redox Modulation of Signal Transduction and Gene
Expression in HIV Infection: The Role of the Antioxidant Lipoate’, Lipoic
Acid in Health and Disease, Fuchs, Packer, & Zimmer (eds),
Marcel Dekker, Inc., 1997, 435-454 |
|
Fudenberg
HH, ‘Dialysable Lymphocyte Extract (DLyE) in Infantile Onset Autism: A
Pilot Study’, Biotherapy (1996) 9:143-147 |
|
Fukino
H, Hirai M, Hsueh YM, Yamane Y,‘Effect of zinc pretreatment on
mercuric chloride-induced lipid peroxidation in the rat kidney’, Toxicol
Appl Pharmacol 1984 May;73(3):395-401 |
|
Gaffney
GR, Kuperman S, Tsai LY, Minchin S, ‘Morphological evidence for
brainstem involvement in infantile autism’, Biological Psychiatry,
September 1988, 24:578-586 |
|
Gilbert
SG, Grant-Webster KS, ‘Neurobehavioral effects of developmental
methymercury exposure’, Environmental Health Perspectives, 1995
Sept; 103 Suppl 6:135-142 |
|
Gillberg
C, Coleman M, The Biology of the Autistic Syndromes - 2nd Edition,
Mac Keith Press, 1992 |
|
Gillberg
C, Dev Med Child Neurol 37, 23-45 (1995) |
|
Gillberg
C, Gillberg IC, 'Infantile Autism: a total population study of reduced
optimality in the pre-, peri- and neonatal period', Journal of Autism
and Developmental Disorders, 1983, Vol 13, No. 2, pp. 153-166 |
|
Gillberg
C, Svennerholm L, ‘CSF monoamines in autistic syndromes and other
pervasive dev. disorders of early childhood’, British Jour. of
Psychiatry, 1987, No. 151, pp. 89-94 |
|
Gillberg
C, Wing L, ‘Autism: not an extremely rare disorder’, Acta
Psychiatr Scand 1999 Jun;99(6)399-406 |
|
Goldberg
M, Mena I, Miller B, ‘Frontal and temporal lobe dysfunction in autism
and other related disorders: ADHD and OCD’, Latin American Journal
of Nuclear Medicine, July 1999, available online: http://www.alabimnjournal.cl |
|
Golse
B, Debray-Ritzen P, Durosay P, Puget K, Michelson AM, ‘Alterations in
two enzymes: superoxide dismutase and glutathion peroxidase in
developmental infantile psychosis’, Revue Neurologic (Paris)
1978 Nov;134(11):699-705 |
|
Gosselin
RE, Smith RP, Hodge HC, Clinical Toxicology of Commercial Products,
Section III, Therapeutic Index, 'Mercury',
(5th edition), Baltimore,
Williams & Wilkins, 1984: pp262-271. |
|
Grandin
T, ‘Brief Report: Response to National Institutes of Health Report’,
Journal of Autism and Developmental Disorders, 1996, Vol. 26, No.
2, 185-187 |
|
Grandin
T, ‘The Learning Style of People With Autism: An Autobiography’, Teaching
Children with Autism, Kathleen Ann Quill, 33-52 |
|
Grandjean
P, Budtz-Jorgensen E, White RF, Jorgensen PJ, Weihe P, Debes F, Keiding
N, ‘Methylmercury exposure biomarkers as indicators of neurotoxicity
in children aged 7 years’, Am J Epidemiol 1999 Aug 1;
150(3):301-305 |
|
Grandjean
P, Guldager B, Larsen IB, Jergensen PJ, Holmstrup P, ‘Placebo Response
in Environmental Disease’, JOEM 1997 August, Vol. 38, No.
8,707-714 |
|
Grandjean
P, Weihe P, White RF, Debes F, ‘Cognitive performance of children
prenatally exposed to “safe” levels of methylmercury’, Environmental
Research 1998 May; 77(2): 165-172 |
|
Grandjean
P, White RF, Nielsen A, Cleary D, de Oliveira Santos EC,
‘Methylmercury neurotoxicity in Amazonian children downstream from
gold mining’, Environ Health Perspect 1999 Jul;107(7):587-591 |
|
Grundt
IK, Stensland E, Syverson TL, ‘Changes in fatty acid composition of
myelin cerebrosides after treatment of the developing rat with
methylmercury chloride and diethylmercury’. J Lipid Res, 1980
Feb;21(2):162-168 |
|
Gunderson,
VM, Grant KS, Burbacher TM, Fagan 3rd
JF, Mottet, NK, ‘The effect of low-level prenatal methyl mercury
exposure on visual recognition memory in infant’,
Child Dev., 1986, 57(4):1076-1083 |
|
Gunderson,
VM, Grant KS, Burbacher TM, et al, ‘Visual recognition memory deficits
in methyl mercury exposed Macaca fascicularis infants’, Neurotoxicol
Teratol., 1988, 10(4):373-379 |
|
Gupta
S, Aggarwal S, Heads C, ‘Brief Report: Dysregulated Immune System in
Children with Autism: Beneficial Effects of Intravenous Immun Globulin
on Autistic Characteristics’, Journal of Autism and Developmental
Disorders, 1996, Vol. 26, No. 4, 439-452 |
|
Gupta
S, Aggarwal S, Rashanravan B, Lee T, ‘Th1- and Th2-like cytokines in
CD4+ and CD8+ T cells in autism’, J Neuroimmunol 1998 May
1;85(1):106-109 |
|
Haeney
MR, Carter GF, Yeoman WB, Thompson RA, ‘Long-term parental exposure to
mercury in patients with hypogammaglobulinaemia’, British Medical
Journal 1979 2:12-14 |
|
Hagerman
RJ, 'Possible similarities between the fragile X and Asperger syndrome',
American Journal of Diseases of Children, 1987;141:601-602 |
|
Halsey
NA, 'Perspective on the use of thimerosal-containing vaccines',
presentation at the National Vaccine Advisory Committee Workshop on
Thimerosal and Vaccines, August 11-12, 1999, available on
Institute of Vaccine Safety website,
www.vaccinesafety.edu |
|
Halsey
NA, ‘Limiting Infant Exposure to Thimerosal in Vaccines and Other
Sources of Mercury’, JAMA, November 10, 1999, Vol. 282, No. 18 |
|
Hartman
DE, 'Missed diagnoses and misdiagnoses of environmental toxicant
exposure', Diagnostic Dilemmas, Part I, 1998 Sep;21(3):659-671 |
|
Hashimoto
T, Tayama M, Miyazaki M, Sakurama N, Yoshimoto T, Murakawa K, Kuroda Y,
‘Reduced brainstem size in children with autism’, Brain &
Development, 1992, Vol. 14, No. 2, pp. 94-97 |
|
Hashimoto
T, Tayama M, Murakawa K, Yoshimoto T, Miyazaki M, Harada M, Kuroda Y,
‘Development of the brainstem and cerebellum in autistic patients’, Journal
of Autism and Developmental Disorders, 1995, Vol. 25, No. 1, pp.
1-18 |
|
Haznedar
MM, Buchsbaum MS, Metzger M, Solimando A, Spiegel-Cohen J, Hollander E,
‘Anterior Cingulate Gyrus Volume and Glucose Metabolism in Autistic
Disorder’, Amercian Journal of Psychiatry 1997 Aug
154(8):1047-1050 |
|
Hepatitis
Control Report, ‘Uproar over a little-known preservative, thimerosal,
jostles U.S. hepatitis B vaccination policy’, Summer 1999, Vol. 4, No.
2 |
|
Hollander
E, Kaplan A, Cartwright C, Reichman D, ‘Venlafaxine in children,
adolescents, and young adults with autism spectrum disorders: an open
retrospective clinical report’, J Child Neurol, 2000, Feb;15(2):132-135 |
|
Hoon
AH and Riess AL, ‘The mesial-temporal lobe and autism: case report and
review’, Developmental Medicine and Child Neurology 1992
34:252-265 |
|
Horvath
K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT,
‘Gastrointestinal abnormalities in children with autistic disorder’,
Journal of Pediatrics 1999 Nov 135(5):559-563 |
|
Hoshino
Y, Watanabe M, Kumashiro H, ‘The hypothalamo-pituitary function in
autistic children: the change of serum 5HT, plasma human growth hormone,
prolactin level after L-5HTP loading’, Neurosciences, 1984,
Vol. 10, pp. 285-291 |
|
Hoshino
Y, Watanabe M, Kumashiro H, ‘The TRH and LH-RH loading test in
autistic children’, Journal of Medical Science, 1985, Vol. 31,
No. 1 |
|
Howlin
P, 'Outcome in adult life for more able individuals with autism or
Asperger syndrome', Autism 2000 Mar;4(1):63-84 |
|
Hrdina
PD, Peters DA, Singhal RL 1976, ‘Effects of chronic exposure to
cadmium, lead and mercury of brain biogenic amines in the rat’, Research
Communications in Chemistry, Pathology and Pharacology 1976 Nov;15(3):483-493 |
|
Hu
H, Abedi-Valugerdi M, Moller G, ‘Pretreatmet of lymphocytes with
mercury in vitro induces a response in T cells from genetically
determine low-responders and a shift of the interleukin profile’, Immunology,
1997 90:198-204 |
|
Hu
H, Möller G, Abedi-Valugerdi M, ‘Major histocompatibility complex
class II antigens are required for both cytokine production and
proliferation induced by mercuric chloride in vitro’, J Autoimmun,
Oct 1997, 10(5):441-446 |
|
Hu
H, Moller G, Abedi-Valugerdi M, ‘Mechanism of mercury-induced
autoimmunity: both T helper 1- and T helper 2-type responses are
involved’, Immunology, March 1999, 96(3):348-357 |
|
Hua
MS, Huang CC, Yang YJ, 'Chronic elemental mercury intoxication:
neuropsychological follow up case study', Brain Inj 1996 May;10(5):377-84 |
|
Hultman
P, Hansson-Georgiadis H, ‘Methyl mercury-induced autoimmunity in
mice’, Toxicol Appl Pharmacol, Feb 1, 1999, 154(3):203-211 |
|
Hultman
P, Nielsen JB, ‘The effect of toxicokinetics on murine mercury-induced
automimunity’, Environ Res, May 1998, 77(2):141-148 |
|
Hultman
P, Turley SJ, Eneström S, Lindh U, Pollard KM, ‘Murine genotype
influences the specificity, magnitude and persistence of murine
mercury-induced autoimmunity’, J Autoimmun, April 1996, 9(2):
139-149 |
|
Hussain
S, Atkinson A, Thompson SJ, Khan AT, ‘Accumulation of mercury and its
effect on antioxidant enzymes in brain, liver, and kidneys of mice’, J
Environ Sci Health B 1999 Jul;34(4):645-660 |
|
Ikeda
M, Komachi H, Sato I, Himi T, Yuasa T, Murota S, ‘Induction of
neuronal nitric oxide synthase by methylmercury in the cerebellum’, Journal
of Neuroscience Research 1999 Feb 1;55(3):352-356. |
|
Ikeda
M, Komachi H, Sato I, Himi T, Yuasa T, Murota S, ‘Induction of
neuronal nitric oxide synthase by methylmercury in the cerebellum’, J
Neurosci Res 1999 Feb 1;55(3):352-356 |
|
Ilback
NG, ‘Effects of methyl mercury exposure on spleen and blood
natural-killer (NK) cell-activity in the mouse’, Toxicology,
1991, 67(1):117-124 |
|
Islam
MS, Berggren PO, Larsson O, ‘Sulfhydryl oxidation induces rapid and
reversible closure of the ATP-regulated K+ channel in the pancreatic
beta cell’, FEBS Lett 1993 Mar 15;319(1-2):128-132 |
|
Jaffe
JS, et al, ‘Functional abnormalities of CD8+ t cells define a unique
subset of patients with common variable immunodeficiency’, Blood,
1993, 82.1.192-2001 |
|
Jaselskis
C, Cook E, Fletcher K, and Bennett L, ‘Clonidine treatment of
hyperactive and impulsive children with autistic disorder’, Journal
of Clinical Psychopharmacology 1992 |
|
Johansson
U, Hansson-Georgiadis H, Hultman P, ‘The genotype determines the B
cell response in mercury-treated mice’, Int Arch Allergy Immunol,
Aug 1998, 116(4):295-305 |
|
Joselow
MM, Louria DB, Browder AA, ‘Mercurialism: Environmental and
Occupational Aspects’, Annals of Internal Medicine 1972
76:119-130 |
|
Joseph
SK, Ryan SV, Pierson S, Renard-Rooney D, Thomas AP, ‘The effect of
mersalyl on inositol trisphosphate receptor binding and ion channel
function’, J Biol Chem 1995 Feb 24;270(8):3588-3593 |
|
Journal
of Autism and Developmental Disorders, 1995,
Vol. 25, No. 2 |
|
Kabuto
M,‘Chronic effects of methylmercury on the urinary excretion of
catecholamines and their responses to hypoglycemic stress’, Arch
Toxical 1991;65(2):164-167 |
|
Kanner
L, ‘Autistic Disturbances of Affective Contact’, The Nervous
Child 1942-1943, Vol. 2, No. 3, 217-250 |
|
Karhapaa
l, Titievsky A, Kaila K, Tornquist K, ‘Redox modulation of calcium
entry and release of intracellular calcium by thimerosal in GH4C1
pituitary cells’, Cell Calcium 1996 Dec;20(6):447-457 |
|
Kark
RA, Poskanzer DC, Bullock JD, Boylen G. ‘Mercury poisoning and its
treatment with N-acetyl-D, L-penicillamine’, New England Journal of
Medicine 1971;285:10-16 |
|
Kates
WR, Mostofsky SH, Zimmerman AW, Mazzocco MM, Landa R, Warsofsky IS,
Kaufmann WE, Reiss AL, ‘Neuroanatomical and neurocognitive differences
in a pair of monozygous twins discordant for strictly defined autism’,
Ann Neurol 1998 Jun; 43(6):782-791 |
|
Kinoshita
Y, Ohnishi A, Kohshi K, Yokota A, ‘Apparent diffusion coefficient on
rat brains and nerves intoxicated with methylmercury’, Environ Res
1999 May;80(4):348-354. |
|
Klin
A, Sparrow SS, de Bildt A, Cicchetti DV, Cohen DJ, Volkmar FR, 'A Normed
Study of Face Recognition in Autism and Related Disorders', Journal
of Autism and Developmental Disorders December 1999 29:6 499-508 |
|
Koegel
LK, Koegel RL, Smith A, ‘Variables Related to Differences in
Standardized Test Outcomes For Children with Autism’, Journal of
Autism and Developmental Disorders, 1997, Vol. 27, No. 3, 233-243 |
|
Koos
BJ and Longo LD, ‘Mercury toxicity in the pregnant woman, fetus, and
newborn infant’, American Journal of Obstetrics and Gynecology
1976 Oct 126(3):390-406 |
|
Kugler
B, 'The differentiation between autism and Asperger syndrome', Autism,
1998 Mar;2(1):11-32 |
|
Kurita
H, ‘Infantile autism with speech loss before the age of thirty
months’, Journal of the American Academy of Child Psychiatry,
1985, Vol. 24, Issue 2, pp. 191-196 |
|
LaCamera
RG, LaCamera AC, 'Routine Health Care', Handbook of Autism and
Pervasive Developmental Disorders, Cohen D, Donnellan AM, Paul R,
eds, 1987 by John Wiley & Sons, Inc., p584-595 |
|
Larkfors
L, Oskarsson A, Sundberg J, Ebendal T, ‘Methylmercury induced
alterrations in the nerve growth factor level in the developing
brain’, Brain Res Dev Brain Res 1991 Oct 21; 62(2) 287-291 |
|
Leboyer
M, Philippe A, Bouvard M, Guilloud-Bataille M, Bondoux D, Tabuteau F,
Feingold J, Mouren-Simeoni MC, Launay JM, 'Whole blood serotonin and
plasma beta-endorphin in autistic probands and their first-degree
relatives', Biol Psychiatry 1999 Jan 15;45(2):158-63 |
|
Lewine
'Magnetoenchalography in Children with an Autistic Epileptiform
Regression', J Pediatrics, 1999 405-418 |
|
Lewis
MH, ‘Brief Report: Psychopharmacology of Autism Spectrum Disorders’,
Journal of Autism and Developmental Disorders, 1996, Vol. 26, No.
2, 231-235 |
|
Li
S, Thompson SA, Woods JS, ‘Localization of gamma-glutamylcysteine
synthetase mRNA expression in mouse brain following methylmercury
treatment using reverse transcription in situ PCR amplification’, Toxicol
Appl Pharmacol, Sept 1996, 140(1):180-187 |
|
Lombard
J, ‘Autism: a mitochondrial disorder?’, Medical Hypotheses
1998 Jun;50(6):497-500 |
|
Lorscheider
FL, Vimy MJ, Summers AO, ‘Mercury exposure from “silver” tooth
fillings: emerging evidence questions a traditional dental paradigm’, The
FASEB Journal, April 1995, Vol. 9, 504-508 |
|
Lowell
JA, Burgess S, Shenoy S, Curci JA, Peters M, Howard TK, ‘Mercury
Poisoning Associated with High-Dose Hepatitis-B Immune Globulin
Administration After Liver Transplantation for Chronic Hepatitis B’, Liver
Transplantation and Surgery, Nov 1996, Vol. 2, No. 6, 475-478 |
|
Magos
L, Brown AW, Sparrow S, Bailey E, Snowden RT, Skipp WR, ‘The
comparative toxicology of ethyl- and methylmercury’, Archives of
Toxicology, 1985 Sep;57(4):260-267 |
|
Malhotra
S, Gupta N, 'Childhood Disintegrative Disorder', Journal of Autism
and Developmental Disorders Dec 1999 29;6 491-498 |
|
Markovich
D, Knight D, 'Renal Na-Si Cotransporter NaSi-1 is inhibited by heavy
metals', American Journal of Renal Physiology, February 1998,
Vol. 274, No. 2, pp283-289 |
|
Marty
MS, Atchison WD, ‘Elevations of intracellular Ca2+ as a probable
contributor to decreased viability in cerebellar granule cells following
acute exposre to methyl mercury’, Toxicol Appl Pharmacol 1998
May’ 150(1):98-105 |
|
Matheson
DS, Clarkson TW, Gelfand EW, ‘Mercury toxicity (acrodynia) induced by
long-term injection of gammaglobulin’, Journal of Pediatrics
1980;97(1):153-155. |
|
Mathiesen
T, Ellingsen DG, Kjuus H, ‘Neuropsychological effects associated with
esposure to mercury vapor among former chloralkali workers’, Scand
J Work Environ Health, 1999, Aug:25(4):342-350 |
|
Mattsson
JR, Miller E, Alligood JP, Koering JE, Levin SG, ‘Early effects of
methylmercury on the visual evoked response of the dog’, Neurotoxicology
1981 Nov;2(3):499-514 |
|
McClelland
RJ, Eyre D, Watson D, Calvert J, ‘A neurophysiological study of
autistic children’, Electroencephalography and Clinical
Neurophysiology, Sept. 1985, Vol. 61, p. 16 |
|
McClelland
RJ, Eyre DG, Watson D, Calvert GJ, Sherrard E, British Journal of
Psychiatry, 1992, 160:
659-663 |
|
McDougle
C, Psycholopharmacology, Handbook of Autism and Pervasive
Developmental Delay, 2nd ed. New York: John Wiley and
Sons, 1997;707:729 |
|
McDougle
CJ, Brodkin ES, Yeung PP, Naylor ST, Cohen DJ, Price LH, ‘Risperidone
in adults with autism or pervasive developmental disorder’, Journal
of Child and Adolescent Psychopharmacology, 1995, Vol. 5, No. 4, pp.
273-282 |
|
McDougle
CJ, Homes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ,
‘Risperidone treatment of children and adolescents with pervasive
developmental disorders: A prospective open-label study’, Journal
of the American Academy of Child and Adolescent Psychiatry, 36,
685-693 |
|
McKay
SJ, Reynolds JN, Racz WJ, ‘Effects of mercury compounds on the
spontaneous and potassium-evoked release of [3H]dopamine from mouse
striatal slices’, Canadian Journal of Physiology and Pharmacology
1986 Dec 64(12):1507-1514 |
|
McKeown-Eyssen
GE, Ruedy J, Neims A, ‘Methyl mercury exposure in northern Quebec: II.
Neurologic findings in children’, Am. J. Epidemiol., 1983,
118:470-479 |
|
Merck
& Co., Inc., ‘Merck Launches Preservative-Free Hepatitis-B
Vaccine’, press release, Sept 9, 1999 |
|
Messahel
S, Pheasant AE, Pall H, Ahmed-Choudhury J, Sungum-Paliwal RS, Vostanis
P, ‘Urinary levels of neopterin and biopterin in autism’, Neurosci
Lett 1998 Jan 23;241(1):17-20 |
|
Minnema
DJ, Cooper GP, Greenland RD, ‘Effects of methylmercury on
neurotransmitter release from rat brain synaptosomes’, Toxicology
and Applied Pharmacology 1989 Jul 99(3):510-521 |
|
Minshew
NJ, ‘Brief Report: Brain Mechanisms in Autism: Functional and
Structural Abnormalities’, Journal of Autism and Developmental
Disorders, 1996, Vol. 26, No. 2, 205-209 |
|
Moreno
H, Borjas L, Arrieta A, Saez L, Prassas A, Estevez J, Bonilla E,
‘Clinical heterogeneity of the autistic syndrome: a study of 60
families’ (Spanish), Invest Clin 1992;33(1):13-31 |
|
Moreno-Fuenmayor
H, Borjas L, Arrieta A, Valera V, Socorro-Candanoza L, ‘Plasma
excitory amino acids in autism’, Invest Clin 1996 Jun;37(2):113-128 |
|
Muris
P, Steerneman P, Merckelbach H, Holdrinet I, Meesters C, ‘Comorbid
anxiety symptoms in children with pervasive developmental disorders’, Journal
of Anxiety Disorders, 1998, Vol. 12, No. 4, pp. 387-393 |
|
Musiek
FE, Hanlon DP, ‘Neuroaudiological effects in a case of fatal
dimethylmercury poisoning’, Ear Hear 1999 Jun;20(3):271-275 |
|
Nass
R, Gross A, Devinsky O, 'Autism and autistic epileptiform regression
with occipital spikes',Dev Med Child Neurol 1998 Jul;40(7):453-8 |
|
‘Neville’s
(a Pinkie) Recollection of Pink Disease’, Pink Disease Support Group, www.users.bigpond.com/difarnsworth |
|
Nielsen
JB and Hultman P, ‘Experimental studies on genetically determined
susceptibility to mercury-induced autoimmune response’, Renal
Failure 1999 21(3&4):343-348 |
|
Nishio
H, Nezasa K, Hirano J, Nakata Y, ‘Effects of thimerosal, an organic
sulfhydryl modifying agent, on serotonin transport activity into rabbit
blood platelets’, Neurochemistry International 1996
29(4):391-396 |
|
Nordin
V, Gillberg C, ‘Autism Spectrum disorders in children with physical or
mental disability or both. I: Clinical and epidemiological aspects’, Dev
Med Child Neurol 1996 Apr; 38(4):297-313 |
|
Nowell
MA, Hackney DB, Muraki AS, Coleman M, 'Varied MR appearance of autism:
fifty-three pediatric patients having the full autistic syndrome', Magn
Reson Imaging 1990;8(6):811-6 |
|
O’Carroll
RE, Masterton G. Dougnall N. Ebmeier KP, 1995, ‘The neuropsychiatric
sequelae of mercury poisoning: The Mad Hatter’s disease revisited’, British
Journal of Psychiatry 167(1):95-98 (1995) |
|
O’Kusky
JR, Boyes BE, McGeer EG, ‘Methylmercury-induced movement and postural
disorders in developing rat: regional analysis of brain catecholamines
and indoleamines’, Brain Research 1988 Jan 26;439(1-2):138-146 |
|
O’Neill
JL, Through the Eyes of Aliens, Jessica Kingsley Publishers Ltd.,
1999 |
|
O’Neill
M, Jones RSP, ‘Sensory-Perceptual Abnormalities in Autism: A Case For
More Research?’, Journal of Autism and Developmental Disorders,
1997, Vol. 27, No. 3, 283-293 |
|
O’Reilly
BA and Waring, R, ‘Enzyme and sulfur oxidation deficiencies in
autistic children with known food/chemical intolerances’, Journal
of Orthomolecular Medicine 1993 4:198-200 |
|
Ono
B, Sakamoto E, ‘Saccharomyces cerevisiae strains sensitive to
inorganic mercury. I. Effect of tyrosene’, Curr Genet
1985;10(3):179-185 |
|
Ono
B, Sakamoto E, Yamaguchi K, ‘Saccharomyces cerevisiae strains
sensitive to inorganic mercury. III. Tyrosine uptake’, Curr Genet
1987;11(5):399-406 |
|
O'Reilly
B, Waring R,
'Enzyme and Sulphur Oxidation Deficienceies in Autistic Children
with Known Food/Chemical Intolerences', pp. 249-252 |
|
Ornitz
EM, ‘Neurophysiologic Studies of Infantile Autism’, Handbook of
Autism and Pervasive Developmental Disorders, John Wiley & Sons,
Inc., 1987, 148-165 |
|
Otsuka
H, 'Brain Metabolites in the Hippocampus-amygdala Region and Cerebellum
in Autism: an 1H-MR Spectroscopy Study', Neuroradiology 1999 Jul |
|
Page
T, Coleman M, ‘Purine metabolism abnormalities in a hyperuricosuric
subclass of autism’, Biochim Biophys Acta, 2000 Mar
17;1500(3):291-296 |
|
Page
T, Yu A, Fontanesi J, Nyhan WL, ‘Developmental disorder associated
with increased cellular nucleotidase activity’, Proc. Natl. Acad.
Sci. USA, Vol. 94, October 1997, 11601-11606 |
|
Paul
R, ‘Natural History’, Handbook of Autism and Pervasive
Developmental Disorders, John Wiley & Sons, Inc., 1987, 121-132 |
|
Pedersen
MB, Hansen JC, Mulvad G, Pedersen HS, Gregersen M, Danscher G,
‘Mercury accumulations in brains from populations exposed to high and
low dietary levels of methyl mercury.
Concentration, chemical form and distribution of mercury in brain
samples from autopsies’, Int J Circumpolar Health 1999
Apr;58(2): 96-107 |
|
Pediatrics
1999; 104:570-574, 'Thimerosal in vaccines: an interim report to
clinicians', Committee on Infectious Disease and Committee on
Environmental Health |
|
Pendergrass
JC, Haley BE, Vimy MJ, Winfield SA, Lorscheider FL, ‘Mercury vapor
inhalation inhibits binding of GTP to tubulin in rat brain: similarity
to a molecular lesion in Alzheimer diseased brain’, Neurotoxicology
1997;18(2):315-324 |
|
Perry
E, Lee M, Court J, Perry R, 'Cholinergic Activities in Autism: Nicotinic
and Muscarinic Receptor Abnormalities in the Cerebral Cortex' ,
presentation to Cure Autism Now, 2000 |
|
Pfab
R, Muckter H, Roider G, Zilker T, ‘Clinical course of severe poisoning
with thiomersal’, Clinical Toxicology 1996;34(4):453-460 |
|
Pierce
PE, Jon F. Thompson, MPH William H. Likosky, MD; Laurance N. Nickey, MD;
William F. Barhtel; and Alan R. Hinman, MD, MPH, ‘Alkyl Mercury
Poisoning in Humans’, JAMA 1972 Vol 220, No11 1439-1442 |
|
Piikivi
L, Hanninen H, Martelin T, et al, ‘Psychological performance and
long-term exposure to mercury vapors’, Scand. J. Work Environ.
Health, 1984, 10:35-41 |
|
Piikivi
L, Tolonen U, ‘EEG findings in chlor-alkaliworkers subject to low long
term exposure to mercury vapor’, Br. J. Ind. Med., 1989,
46(6):370-375 |
|
Pirker
C, Möslinger T, Wantke F, Götz, Jarisch R, ‘Ethylmercuric chloride:
the responsible agent in thimerosal hypersensitivity’, Contact
Dermatitis 1993:29:152-154 |
|
Piven
J, Berthier M, Starkstein S, Nehme E, Pearlson G, Folstein S,
‘Magnetic resonance imaging evidence for a defect of cerebral cortical
development in autism’, American Journal of Psychiatry, June
1990, 147:6, pp. 734-739 |
|
Piven
J, Palmer P, ‘Psychiatric disorder and the broad autism phenotype:
evidence from a family study of multiple-incidence autism families’, American
Journal of Psychiatry, April 1999, Vol. 156, No. 4, pp. 557-563 |
|
Pless
R, 'Summary of the Workshop on Thimerosal in Vaccines', Report from the
National Immunization Program, CDC, 1999 |
|
Plioplys
A, 'Autism: Biomedical Perspectives', Presentation for the Autism
Society of America meeting, July 1989 |
|
Plioplys
AV, Greaves A, Kazemi K, Silverman E, ‘Immunoglobin reactivity in
autism and Rett’s syndrome’, Developmental Brain Dysfunction,
1994, 7:12-16 |
|
Plioplys
AV, Greaves A, Kazemi K, Silverman E, ‘Lymphocyte function in autism
and Rett Syndrome’, Neuropsychobiology 1994;29(1) :12-6 |
|
Plioplys
AV, Hemmens SE, Regan CM, 'Expression of a neural cell adhesion molecule
serum fragment is depressed in autism', J Neuropsychiatry Clin
Neurosci, 1990 Fall;2(4):413-7 |
|
Plotkin
S, Orenstein W, Vaccines 1999 |
|
Prechtl
HFR, 'Neurological Findings in Newborn Infants after Pre- and Paranatal
complications', Jonxis et al editors:Aspects of Prematurity and
Dysmaturity: a Nutrica symposium, Leiden:Stenfert Kroesse, 1968 |
|
Prizant
BM, ‘Brief Report: Communication, Language, Social, and Emotional
Development’, Journal of Autism and Developmental Disorders,
1996, Vol. 26, No. 2, 173-178 |
|
Purine
Research Society, 'What We Learn About Metabolic Disease Will Benefit
Each and Every One of Us', Purine Research Society Website |
|
Puschel
G, Mentlein R, Heymann E, 'Isolation and characterization of dipeptidyl
peptidase IV from human placenta', Eur J Biochem 1982 Aug;126(2):359-65 |
|
Rajanna
B and Hobson M, ‘Influence of mercury on uptake of [3H]dopamine and
[3H]norepinephrine by rat brain synaptosomes’, Toxicology Letters 1985
Sep 27(1-3):7-14 |
|
Rajanna
B, Hobson M, Harris l, Ware L, Chetty CS, ‘Effects of cadmium and
mercury on Na(+)-K+, ATPase and uptake of 3H-dopamine in rat brain
synaptosomes’, Arch Int Physiol Biochim 1990 Oct;98(5):291-296 |
|
Rice
D, 'Lack of Effect of Methylmercury Exposure from Birth to Adulthood on
Information Processing Speed in the Monkey', September 1997, |
|
Rice
DC, ‘Sensory and cognitive effects of developmental methylmercury
exposure in monkeys, and a comparison to effects in rodents’, NeuroToxicol.,
1996, 17:139-154 |
|
Rice
DC, Gilbert SG, ‘Early chronic low-level methylmercury poisoning in
monkeys impairs spatial vision’ Science 1982 May
14;216(4547):759-761 |
|
Richdale
AL, 'Sleep problems in autism: prevalence, cause, and intervention', Developmental
Medicine and Child Neurology, 1999 Jan 41(1):60-6 |
|
Rimland
B, ‘Recovery from autism is possible’, cited in Autism Research
Review International, 1994, Vol. 8, No. 2, p. 3 |
|
Rimland
B, Baker SM, ‘Brief Report: Alternative Approaches to the Development
of Effective Treatments for Autism’, Journal of Autism and
Developmental Disorders, 1996, Vol. 26, No. 2, 237-241 |
|
Ritvo
ER, Freeman BJ, Scheibel AB, Duong T, Robinson H, Guthrie D, Ritvo A,
'Lower Purkinje cell counts in the cerebella of four autistic subjects:
intitial findings of the UCLA-NSAC Autopsy Research Report', American
Journal of Psychiatry, 1986;143:862-866 |
|
Ritvo
ER, Freeman BJ, Creel D, Crandall AS, Pingree C, Barr R, Realmuto G,
‘Retinal Pathology in Autistic Children – A Possible Biological
Marker for Subtype?’ (letter), Journal of the American Academy of
Child Psychiatry, January 1986, 25:137 |
|
Rodier
PM, Ingram JL, Tisdale B, Croog VJ, ‘Linking etiologies in humans and
animal models: studies of autism’, Reproductive Toxicology,
1997, Vol. 11, Nos. 2/3, pp. 417-422 |
|
Rodier,
P.M., M. Aschner and P. R. Sager. 1984. Mitotic arrest in the developing
CNS after prenatal exposure to methyl mercury. Neurobehav. Toxical.
Teratol. 6:379-385. |
|
Rogers
SJ, ‘Brief Report: Early Intervention in Autism’, Journal of
Autism and Developmental Disorders, 1996, Vol. 26, No. 2, 243-246 |
|
Rogers
T, Kalaydjieva, Hallmayer et al, 'Exclusion of Linkage to the HLA Region
in Ninety Multiplex Sibships with Autism', Journal of Autism and
Developmental Disorders, 1999 Jun;29(3):195-202 |
|
Rohyans
J, Walson PD, Wood GA, MacDonald WA, ‘Mercury toxicity following
merthiolate ear irrigations’, The Journal of Pediatrics, 1984
Feb:311-313 |
|
Romani
L, ‘Immunity to Candida albicans: Th1, TH2 cells and beyond’, Curr
Opin Microbiol 1999 Aug;2(4): 363-367 |
|
Rosenhall
U, Johansson E, Gillberg C, ‘Oculomotor findings in autistic
children’, Journal of Laryngology and Otology, May 1988, Vol.
102, pp. 435-439 |
|
Rosenhall
U, Nordin V, Sandstrom M, Ahlsen G, Gillberg C, 'Autism and Hearing
Loss', Journal of Autism and Developmental Disorders, Oct 1999
29(5) 349-358 |
|
Ross
W. Donald, Gechman A, Sholiton M, Paul H, 'Alertness to Neuropsychiatric
Manifestations', Comprehensive Psychiatry, Vol. 18, No. 6, pp.
595-598 |
|
Rossi
AD, Ahlbom E, Ogren So, Nicotera P, Ceccatelli S, ‘Prenatal exposure
to methylmercury alters locomotor activity of male but not female
rats’, Exp Brain Res 1997 Dec;117(3):428-436 |
|
Roux
S, Adrien J-L, Bruneau N, Malvy J, Barthelemy C, 'Behavior Profiles
within a population of 145 children with autism using the Behaviour
Summarized Evaluation scale: influence of developmental age', Autism,
1998 (Dec) 2(4) 235-266 |
| Rumsey
J, ‘Conceptual problem-solving in highly verbal, nonretarded autistic
men’, Journal of Autism and Dev. Disorders,
1985, Vol. 15, No. 1, pp. 23-36 |
|
Rumsey
JM, Hamburger SD, ‘Neuropsychological findings in high-functioning men
with infantile autism, residual state’, Journal of Clinical and
Experimental Neuropsychology, 1988, Vol. 10, No. 2, pp. 201-221 |
|
Russell
J, Jarrold C, Hood B, ‘Two Intact Executive Capacities in Children
with Autism: Implications for the Core Executive Dysfunctions in the
Disorder’, Journal of Autism and Developmental Disorders, 1999,
Vol. 29, No. 2, 103-112 |
|
Rutter
M, 'Autism research: prospects and priorities', Journal of Autism and
Developmental Disorders 1996 Apr;26(2):257-75 |
|
Rutter
M, ‘The development of infantile autism’, Psychological Medicine
1974 4:147-163 |
|
Ryu
YH, Lee JD, Yoon PH, Kim DI, Lee HB, Shin YJ, ‘Perfusion impairments
in infantile autism on technetium-99m ethyl cysteinate dimer brain
single-photon emission tomography: comparison with findings on magnetic
resonance imaging’, Eur J Nucl Med 1999 Mar;26(3):253-259 |
|
Sager.
P.R., Aschner, M., and Rodier, P.M. 'Persistent differential alteration
in developing cerebellar cortex of male and female mice after
methylmercury exposure', Dev. Brain Res. 12: 1-11 (1984) |
|
Sarafian
TA, Bredesen DE, Verity MA, ‘Cellular resistance to methylmercury’, Neurotoxicology,
1996 Spring Abstract, 17(1):27-36 |
|
Sayers
LG, Brown GR, Michell RH, Michelangeli F, ‘The effects of thimerosal
on calcium uptake and inositol 1,4,5-triosphate-induced calcium release
in cerebellar microsomes’, Biochem J 1993 Feb 1;289 (Pt
3):883-887 |
|
Schuler
AL, ‘Thinking in Autism: Differences in Learning and Development’, Teaching
Children with Autism, Kathleen Ann Quill, ed., 1995, 11-32 |
|
Sears
LL, 'An MRI Study of the Basal Ganglia in Autism', Prog
Neuropsychopharmacol Biol Psychiatry, 1999 May |
|
Shafer
TJ, Atchison WD, ‘Transmitter, ion channel and receptor properties of
pheochromocytoma (PC12) cells: a model for neurotoxicological
studies’, Neurotoxicology 1991 Fall;12(3):473-492 |
|
Shattock
P, Savery D, Autism as a Metabolic Disorder, Autism Research
Unit, University of Sunderland, Sunderland, UK, 1997 |
|
Shenker
BJ, Datar S, Mansfield K, Shapiro IM, ‘Induction of apoptosis in human
T-cells by organomercuric compounds: a flow dytometric analysis’, Toxicol
Appl Pharmacol, April 1997, 143(2): 397-406 |
|
Shenker
BJ, Guo TL, Shapiro IM, ‘Low-level methylmercury exposure causes human
T-cells to undergo apoptosis: evidence of mitochondrial dysfunction’, Environmental
Research, 1998 May; Section A 77(2):149-159 |
|
Shenker,
B.J., Berthold, P., DeBolt, K., Rooney, C., Vitale, L.A., and Shapiro,
I.M. (1992). 'Immunotoxic
effects of mercuric compounds on human lymphocytes and monocytes.
II. Alterations in
cell viability', Immunopharm. Immunotox. 14, 555-577. |
|
Shenker,
B.J., Berthold, P., Decker, S., Mayro, J.S., Rooney, C., Vitale, L.A.,
and Shapiro, I.M. (1993). 'Immunotoxic
effects of mercuric compounds on human lymphocytes and monocytes. III.
Alterations in B-cell function and viability',
Immunopharm. Immunotox.
15, 87-112. |
|
Siegel
BV, Nuechterlein KH, Abel L, Wu JC, Buchsbaum MS, ‘Glucose metabolic
correlates of continuous performance test performance in adults with a
history of infantile autism, schizophrenics, and controls’, Schizophrenia
Research 1995 Sep 17(1):85-94 |
|
Sigman
M, Ungerer JA, Mundy P, Sherman T, ‘Cognition in Autistic Children’,
Handbook of Autism and Pervasive Developmental Disorders, John
Wiley & Sons, Inc., 1987, 103-130 |
|
Singh
VK, 'Plasma increase of Interleuken-12 and Interferon-gamma.
Pathological significance in autism', J Neuroimmunology, 1996 May;66(1-2):143-5 |
|
Singh
VK, Warren RP, Odell D, 'Immune response to brain myelin in autistic
children', July 1992 |
|
Singh
V, Warren R, Odell J, Warren W, Cole P, 'Antibodies to myelin basic
protein in children with autistic behavior', Brain, Behavior and
Immunity, 1993 Mar;7(1):97-103 |
|
Singh
VK et al, Biological Psychiatry 1997 41: 753-755 |
|
Singh
VK, Fudenberg HH, Emerson D, Coleman M, ‘Immunodiagnosis and
immunotheraphy in autistic children’, Annals of the New York
Academy of Science, 540, 1988, 602-604 |
|
Singh
VK, Journal of Neuroimmunology 1996 66: 143-145 |
| Singh,VK
et al, Brain, Behavior and
Immunity
1993 7: 97-103 -
http://www.whale.to/vaccines/binstock5.html |
|
Smalley
SL, Collins F, ‘Brief Report: Genetic, Prenatal, and Immunologic
Factors’, Journal of Autism and Developmental Disorders, 1996,
Vol. 26, No. 2, 195-198 |
|
Smith
D., 'Mental Effects of Mercury Poisoning',
Presentation before the Section on Family Practice, Southern
Medical Association, 71st Annual Scientific Assembly,
November 6-9, 1977 |
|
Snyder
RD. ‘The involuntary
movements of chronic mercury poisoning’, Archives of
Neurology 1972;26:379-3381 |
|
Sperry
VW, 'Family and personal section: From the inside out - a view of the
world as seen by one with Asperger syndrome', Autism, 1998 Marc;2(1):81-86 |
|
Sternberg
RJ, 'A Unified Theoretical Perspective on Autism', Handbook
of Autism and Pervasive Developmental Disorders, Cohen DJ, Donnellan AM,
Paul R, eds, 1987 by John Wiley & Sons, p.690-696 |
|
Stevenson
RE, Schroer RJ, Skinner C, Fender D, Simensen RJ, 'Autism and
macrocephaly', Lancet, 1997, 349:1744-1745 |
|
Stores
G, Wiggs L, 'Abnormal sleeping patterns associated with autism: a brief
review of research findings, assessment methods and treatment
strategies', Autism, 1998 Jun;2(2):157-170 |
|
Stubbs
EG, ‘Autistic children exhibit undetectable
hemagglutination-inhibition antibody titers despite previous rubella
vaccination’, Journal of Autism and Childhood Schizophrenia, 6,
269-274, 1976 |
|
Sutton
KG, McRory JE, Guthrie H, Murphy TH, Snutch TP, 'P/Q-type calcium
channels mediate the activity-dependent feedback of syntaxin-1A', Nature
1999 Oct 21;401(6755):800-4 |
|
Szasz
A, Barna B, Szupera Z, De Vixxcher G, Galbacx Z, Kirsch-Volders M,
Szente M, ‘Chronic low-dose maternal exposure to methylmercury
enhances epileptogenicity in developing rats’, Int J. Devl Neurosci,
1999, 17.7.733-742 |
|
Szatmari
P, Bartolucci G, Bremner R, Bond S, Rich S, ‘A follow-up study of
high-functioning autistic children’, Journal of Autism and
Developmental Disorders, June 1989, Vol. 19, No. 2, pp. 213-225 |
|
Tan
XX, Tang C, Castoldi AF, Manzo L, Costa LG, ‘Effects of inorganic and
organic mercury on intracellular
calcium levels in rat T lymphocytes’, Journal of Toxicology &
Environmental Health, 1993 Feb;38(2):159-170 |
| Teitelbaum
P, Teitelbaum O, Nye J, Fryman J, Maurer RG, ‘Movement analysis in
infancy may be useful for early diagnosis of autism’, Proc. Natl.
Acad. Sci. USA,
Vol. 95, November 1998, 13982-13987 |
|
The
MAAP,
Volume IV, 1996; Volume VI, 1996; Volume III, 1999; Volume IV, 1997;
Volume II, 1997; Volume I, 1997; Volume II, 1998; Volume IV, 1998, MAAP
Services, Inc., PO Box 524, Crown Point, IN 46308 |
|
Thrower
EC, Duclohier H, Lea EJ, Molle G, Dawson AP, ‘The inositol
1,4,5-trisphosphate-gated Ca2+ channel: effect of the protein thiol
reagent thimerosal in channel activity’, Biochem J 1996 Aug
15;318 (Pt 1): 61-66 |
|
Tokuomi
H. Uchino M. Imamura S. Yamanaga H. Nakanishi R. Ideta T, ‘Minamata
disease (organic mercury poisoning):
Neuroradiologic and electrophysiologic studies’,
Neurology 1982;32:1369-1375) |
|
Tonge
BJ, Brereton AV, Gray KM, Einfeld SL, 'Behavioural and emotional
disturbance in high-functioning autism and Asperger's syndrome', Autism,
1999 Jun;3(2):117-130 |
|
Trottier
G, Srivastava L, Walker CD, ‘Etiology of Infantile Autism: a review of
recent advances in genetic & neurobiological research’, Journal
of Psychiatry & Neuroscience, 1999 March 24(2):103-115 |
|
Tsai
LY, 'Brief Report: Comorbid Psychiatric Dosorders of Autistic Disorder',
Journal of Autism and Developmental Disorders, April 1996
26(2)159-164 |
|
Tuunanen
J, Halonen T, Pitkanen A, ‘Decrease in somatostatin-immunoreactive
neurons in the rat amygdaloid complex in a kindling model of temporal
lobe epilepsy’, Eiplepsy Res, 1997, 26.315-327 |
|
Tuunanen
J, Halonen T, Pitkanen A, ‘Status epilepticus causes selective
regional damage and loss of GABAergic neurons in the rat amygdaloid
complex,’ Eur J Neurosci, 1996, 8:2711-2725 |
|
Tuunanen
J, Lukasiak K, Halonen T, Pitkanen A, ‘Status epilepticus-induced
neuronal damage in the rat amygdaloid complex: distribution, time-course
and mechanisms’, Neurosci, 1999, 94.2.473-495 |
|
Uchida
T, Naito S, Kato H, Hatano I, Harashima A, Terada Y, Ohkawa T, Chino F,
& Eto K, ‘Thimerosal induces toxic reaction in non-sensitized
animals’, International Archives of Allergy & Immunology,
1994 104(3):296-301 |
|
Vahter
M, Mottet NK, Friberg L, Lind B, Shen DD, Burbacher T, ‘Speciation of
mercury in the primate blood and brain following long-term exposure to
methyl mercury’, Toxicol Appl Pharmacol, 1994
Feb;124(2):221-229 |
|
Volterra
A, Trotti D, Cassutti P, Tromba C, Salvaggio A, Melcangi RC, Racagni G,
‘High sensitivity of glutamate uptake to extracellular free
arachidonic acid levels in rat cortical synaptosomes and astrocytes’, Journal
of Neurochemistry 1992 Aug 59(2):600-606 -
http://www.autism.com/triggers/vaccine/mercury.htm
|
|
Von
Burg R, Rustam H, ‘Conduction Velocities in Methylmercury Poisoned
Patients’, Bulletin of Environmental Contamination & Toxicology,
1974, 12(1):81-85 |
|
Von
Burg R, Rustam H, ‘Electrophysiological Investigations of
Methylmercury Intoxication in Humans. Evaluation of Peripheral Nerve by
Conduction Velocity and Electromyography’, Electroencephalography
and Clinical Neurophysiology, 1974, 37:381-392 |
|
Vostanis
P, Smith B, Corbett J, Sungum-Paliwal R, Edwards A, Gingell K, Golding
R, Moore A, Williams J, ‘Parental concerns of early development in
children with autism and related disorders’, Autism, September
1998, Vol. 2, No. 3, 229-242 |
|
Vroom
FQ, Greer M, 'Mercury Vapour Intoxication', Brain (1972) 95,
305-318 |
|
Wakefield
AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M,
Chillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith
JA, ‘Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and
pervasive developmental disorder in children’, The LANCET,
February 28, 1998, Vol. 351, 637-641 |
|
Warfvinge
K, Hua J, Logdberg B, 'Mercury distribution in cortical areas and fiber
systems of the neonatal and maternal cerebrum after exposure of pregnant
squirrel monkeys to mercury vapor', Environ Res 1994 Nov;67(2):196-208 |
|
Warkany
J, Hubbard DH, 'Acrodynia and Mercury', J Pediatrics 1953
42;365-386 |
|
Warren
RP, Margaretten NC, Foster A, ‘Reduced Natural Killer Cell Activity in
Autism’, Journal of the American Academy of Child and Adolescent
Psychiatry, 1987, Vol. 26, No. 3, pp. 333-335 |
|
Warren
RP, Margaretten NC, Pace NC, Foster A, ‘Immune Abnormalities in
Patients with Autism’, Journal of Autism and Developmental
Disorders, 1986, Vol. 16, No. 2, pp. 189-197 |
|
Warren
RP, Odell JD, Warren WL, Burger RA, Maciulis A, Daniels WW, Torres AR,
‘Strong association of the third hypervariable region of HLA-DRß1
with autism’, Journal of Neuroimmunology 67 (1996) 97-102 |
|
Warren
RP, Yonk LJ, Burger RA, Cole P, Odell JD, Warren WL, White E, Singh VK,
'Deficiency of Suppressor-inducer (CD4+CD45RA+) T Cells in Autism', Immunological
Investigations, 1990 Jun 19(3):245-251 |
|
Watanabe
C, Kasanuma Y, Dejima Y, Satoh H, ‘The effect of prenatal
nethylmercury exposure on the GSH level and lipid peroxidation in the
fetal brain and placenta of mice’, Tohoku J Exp Med 1999
Feb;187(2):121-126 |
|
Watzl
B, Abrahamse SL, Treptow-van Lishaut S, Neudecker C, Hansch GM,
Rechkemmer G, Pool-Zobel BL, 'Enhancement of ovalbumin-induced antibody
production and mucosal mast cell response by mercury', Food Chem
Toxicol 1999 Jun;37(6):627-37 |
|
Wecker
L, Miller SB, Cochran SR, Dugger DL, Johnson WD, ‘Trace Element
Concentrations in Hair From Autistic Children’, J. ment Defic. Res.
(1985) 29, 15-22 |
|
Weitzman
A, Weisman R, Szekely GA, Wijsenbeek H, Livni E, 'Abnormal immune
response to brain tissue antigen in the syndrome of autism', Am J
Psychiatry 1982 Nov;139(11):1462-5 |
|
Whiteley
P, Rogers J, Shattock P, ‘Clinical features associated with autism:
observations of symptoms outside the diagnostic boundaries of autistic
spectrum disorders’, Autism, December 1998, Vol. 2, No. 4,
415-422 |
|
Wild
GC, Benzel EC, Essentials of Neurochemistry, Jones and Bartlett
Publishers, Inc., 1994 |
|
Williams
D, Autism - An Inside-Out Approach, 1996, Jessica Kingsley
Publishers Ltd, London |
|
Wing
L, Attwood A, ‘Syndromes of Autism and Atypical Development’, Handbook
of Autism and Pervasive Developmental Disorders, John Wiley &
Sons, Inc., 1987, 3-19 |
|
Wing,
Lorna (1996) ‘Autism Spectrum Disorder’, British Medical Journal
312: 327-328 |
|
Wu
J, Takeo T, Kamimura N, Wada J, Suga S, Hoshina Y, Wakui M,
‘Thimerosal modulates the agonist-specific cytosolic Ca2+ oscillatory
patterns in single pancreatic acinar cells of mouse’, FEBS Lett
1996 Jul 22;390(2):149-152 |
|
Yamagata
T, 'FRAXE mental retardation', Nippon Rinsho 1990 Apr;57(4):955-9 |
|
Yard
BA, Lorentz CP, Herr D, and Van Der Woude F, ‘Sulfation-dependent
down-regulation of interferon-gamma-induced Major Histocompatibility
Complex I and II Intercellular Adhesion Molecule-1 expression on tubular
and endothelial cells by glycosaminoglycans’, Transplantation
Vol.66(9), November 15, 1998, pp. 1244-1250 |
|
Yazbak
FE, ‘Autism ‘99, a national emergency’,
http://www.garynull.com/documents/autism_99.htm
(Internet publication) 1999 |
|
Yeates
KO & Mortensen ME, ‘Acute and chronic neuropsychological
consequences of mercury vapor poisoning in two early adolescents’, Journal
of Clinical Exp Neuropsychology, 1994 16(2):209-222 |
|
Yip
RK, Riley DA, ‘Effects of methylmercury on the motor and sensory and
innervation of the rat extensor digitorum longus muscle’, Environ
Res 1987 Jun;43(1):85-96. |
|
Yuan
Y, and Atchison WD, ‘Comparative effects of methylmercury on
parallel-fiber and climbing fiber responses of rat cerebellar slices’,
Journal of Pharmacology and Experimental Therapy 1999
Mar;288(3):1015-1025. |
|
Zimmerman
A, Brashear R, Frye V, Potter N, 'Anticerebellar Antibodies in Autism',
pp. 275-276 |
|
Zimmerman
A, Frye VH, Potter NT, ‘Immunological aspects of autism’, International
Journal of Pediatrics, 8, 1993, 199-204 |
| Zimmerman
AW, Gonfardin B, Myers SM, Neuropharmacological therapy in autism,
Autism: Clinical and Research Issues, ed. Pasquale
Accardo, et al., Timonium, MD: York Press, 1996 |
|
Altra Bibliografia -
References
1.
Professor Margot Prior, a presentation at the Cato Conference Centre, May
17th, 1999.
First
printed in Austism News September 1999
2.
Changes in Population of Persons with Autism and Pervasive Developmental
Disorders in California's Developmental Services System: 1987-1998, a
Report of the Legislature, March 1, 1999.
3.
Changes in Population of Persons with Autism and Pervasive Developmental
Disorders in California's Developmental Services System: 1987-1998, a
Report of the Legislature, March 1, 1999.
4.
Singh V, Yang V. Serological association of measles virus and human herpes
virus-6 with brain autoantibodies in autism. Clinical Immunology and
Immunopathology 1998;880):105-108.
5.
Massimo Montinari, et aL, Department of Pediatric Surgery, University of
Bari, Italy, presented May 9, 1996
http://www.healthy.net/library/articles/coulter/biochem.htm
6.
Bolte E, "Autism and Clostridium, Tetani: An Hypothesis" [Medical
Hypotheses, vol. 51, 1998, pages 133-144.
7.
Wakefield A.J, et al. fleal-lymphoid-nodular hyperplasia,
non-specific colitis, and pervasive developmental disorder in children.
Lancet 1998;351:637-641. 17. Kumar S, Miller LK. Effects of serial passage
of Autographa California nuclear poly hedrosis virus in cell culture.
Virus Research 1987;7:335-349.
8.
Wakefield et a] (1998) Ileal-lymphoid-nodular hyperplasia, non-specific
colitis, and pervasive developmental disorder in children.
Lancet
351; 637-641.
9.
Martin WJ, et al.
Stealth
virus epidemic in Mohave Valley, 1: Initial report of virus isolation.
Pathobiology 1997;65(l):351-356.
10.
Gupta S, et al. Dysregulate immune system in children with autism,
beneficial effects of intravenous globulin on autistic characteristics. J
of Autism and Developmental Disorders 1996;26(4):439452.
11.
www.autism.com/ari/mercury.html
12.
Gillberg C., Coleman M. The Biology of the Autistic Syndromes, 2nd edn.
London: MacKeith Press, 1992.
13.
Alm JS, et al. Atopy
in children of families with an anthroposophic lifestyle. Lancet
1999;353:1485-1488.
14.
"Elevated Serotonin Levels in Autism: Association With the Major
Histocompatibility Complex." Neuropsychobiology,
vol. 34, number 2, 1996, pp. 72-5
15.
O Reilly B. A., Waring, R. Enzyme and sulphur oxidation deficiencies in
autistic children with known food/chemical intolerances. Journal of
Orthomolecular Medicine 1993; 4: 198-200.
16.
Markovich D., Knight D., Renal Na-Si cotransporter NaSi-1 is inhibited by
heavy metals. American Journal of Renal Physiology 1998; 274(2): Z83-289.
17.
Horvath, Stefanatos, Sokolski, Wachtel, Nabors & Tildon, 1998
18.
Dr Kalle Reichelt, NORWAY
http://osiris.sunderland.ac.uk/autism/sec.htm
19.
VK Singh , Lin SX , Newell E, Nelson C.
Anomalia negli anticorpi morbillo-parotite-rosolia e
autoimmunità del sistema nervoso centrale nei bambini
autistici, J Biomed Sci. lug 2002-ago.
20.
VK
Singh, Lin SX, Yang VC.
Associazione sierologica del virus del morbillo e
dell’herpes virus umano-6 (HHV-6) con gli autoanticorpi
cerebrali nell'autismo,
21. Clin Immunol Immunopathol, Ottobre
1998Richmand BJ.
Ipotesi: vaccini coniugati possono
predisporre i bambini al disturbo dello spettro
autistico, Med Hypotheses.
Dic. 2011
Continua da e in:
Autismo Refenze
2 +
Autismo Refenze
- 3 +
Amish senza autismo
perche' NON vaccinano +
Autismo +
Bibliografia per autismo dai Vaccini
e QUI
http://healthimpactnews.com/2014/the-vaccine-autism-cover-up-how-one-doctors-career-was-destroyed-for-telling-the-truth/
E questa è solo una piccolissima parte della Bibliografia esistente sui
Danni
da vaccino !
VACCINS DAMAGES +
Bibliografia
Danni dei vaccini +
Bibliografia danni
2 +
Bibliografia
+ Bibliografia
2
+
Bibliografia 3
+
Bibliografia 4 +
Sostanze
eterologhe nei vaccini e reazioni
+
INGREDIENTI TOSSICI anche OCCULTI,
di alcuni VACCINI analizzati +
Contenuto nel vaccini Trivalenti
(difpertal) +
Come si producono i Vaccini
|
|